###begin article-title 0
Molecular and functional characterization of polymorphisms in the secreted phospholipase A2 group X gene: relevance to coronary artery disease
###end article-title 0
###begin p 1
###xml 287 294 287 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 402 406 402 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 281 286 <span type="species:ncbi:9606">human</span>
Among secreted phospholipases A2 (sPLA2s), human group X sPLA2 (hGX sPLA2) is emerging as a novel attractive therapeutic target due to its implication in inflammatory diseases. To elucidate whether hGX sPLA2 plays a causative role in coronary artery disease (CAD), we screened the human PLA2G10 gene to identify polymorphisms and possible associations with CAD end-points in a prospective study, AtheroGene. We identified eight polymorphisms, among which, one non-synonymous polymorphism R38C in the propeptide region of the sPLA2. The T-512C polymorphism located in the 5' untranslated region was associated with a decreased risk of recurrent cardiovascular events during follow-up. The functional analysis of the R38C polymorphism showed that it leads to a profound change in expression and activity of hGX sPLA2, although there was no detectable impact on CAD risk. Due to the potential role of hGX sPLA2 in inflammatory processes, these polymorphisms should be investigated in other inflammatory diseases.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 87 89 87 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sn</italic>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 643 644 643 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 740 741 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 446 451 <span type="species:ncbi:9606">human</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
Secreted phospholipases A2 (sPLA2) form a growing family of enzymes that hydrolyze the sn-2 position of glycerophospholipids to generate proinflammatory lipid mediators, lysophospholipids, and free fatty acids. Ten enzymatically active sPLA2s have been identified in mammals. Increased sPLA2 activity has been shown to be an independent risk factor for coronary artery disease (CAD) [1], and group IIA, III, V, and X sPLA2s have been detected in human atherosclerotic lesions [2-5]. The tissue-specific expression pattern and the enzymatic properties of the various sPLA2s suggest that the cellular role of each of these enzymes is different [6]. Studies with transgenic and knockout mice for different sPLA2s support the above hypothesis [4, 7-10].
###end p 4
###begin p 5
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 187 194 187 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1252 1254 1252 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1502 1503 1502 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 1322 1327 <span type="species:ncbi:9606">human</span>
###xml 1466 1471 <span type="species:ncbi:9606">human</span>
Among sPLA2s, the role of human group X sPLA2 (hGX sPLA2) is emerging as several studies show its implication in various inflammatory diseases [8, 9, 11-13]. The gene encoding hGX sPLA2 (PLA2G10) maps to human chromosome 16p13.1-p12. A 1.5-Kb transcript was found in the thymus, spleen, and leukocytes, indicating a possible role for hGX sPLA2 in immunity and/or inflammation [14]. One of the key features of hGX sPLA2 is its high catalytic activity towards phosphatidylcholine (PC), the major phospholipid of cell membranes and lipoproteins. This substrate preference is due to the presence of a tryptophan residue on the interfacial binding surface of the enzyme [15]. On the basis of the structural similarities between platelet-activating factor (PAF) and PC, we demonstrated that hGX sPLA2, but not other sPLA2s, can efficiently hydrolyze PAF when it is incorporated into large unilamellar PC phospholipid vesicles and when it is present in PC-rich lipoproteins [16]. This suggests that hGX sPLA2 may be a novel player in PAF regulation during inflammatory processes. hGX sPLA2 can also efficiently hydrolyze lipoproteins (low-density lipoprotein (LDL) and high-density lipoprotein (HDL)), preferentially releasing arachidonic and linoleic acids [17, 18]. Finally, we have recently shown that hGX sPLA2 is present in human atherosclerotic lesions and that the hydrolysis of LDL by hGX sPLA2 results in a modified LDL particle that induces lipid accumulation in human monocyte-derived macrophages [2].
###end p 5
###begin p 6
###xml 21 28 21 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
Recent studies using PLA2G10-deficient mice in a model of ischemia reperfusion showed that deficiency in GX sPLA2 leads to a reduction in myocardial ischemia reperfusion injury as neutrophil functions were suppressed [11]. Several studies implicated hGX sPLA2 in the pathogenesis of inflammatory diseases such as asthma [9], and recent data support the idea that hGX sPLA2 may be an important therapeutic target in diseases where inflammation plays an important role, including atherosclerosis.
###end p 6
###begin p 7
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
The aim of the present study was to examine the variability of the PLA2G10 gene and to determine whether it plays a role in CAD and its complications. In addition, we examined the potential functional impact of the non-synonymous R38C polymorphism on the expression and activity of the enzyme.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Study populations
###end title 9
###begin p 10
###xml 0 16 0 16 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The SIPLAC study</bold>
###xml 376 398 376 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Etude Cas-T&#233;moins de l</italic>
###xml 399 420 399 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Infarctus du Myocarde</italic>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 760 761 760 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 870 871 868 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 635 643 <span type="species:ncbi:9606">patients</span>
###xml 988 1000 <span type="species:ncbi:9606">participants</span>
The SIPLAC study The SIPLAC study was specifically designed to investigate the variability of candidate genes for myocardial infarction (MI) in groups highly contrasted for disease risk and to further characterize the structure of linkage disequilibrium (LD) within these genes in order to select the polymorphisms that will be genotyped in larger studies. It is derived from Etude Cas-Temoins de l'Infarctus du Myocarde (ECTIM), a case-control study of MI based on the multinational monitoring of trends and determinants in cardiovascular disease project registers in the UK and France [19]. The entire ECTIM study comprised 1,332 MI patients and 1,490 controls (62% from UK, 21% female). For the SIPLAC sub-study, cases with MI and a parental history of MI (n = 312, 35% females, mean age: 56 +/- 16 years) and controls without CAD and without parental history of MI (n = 317, 42% females, mean age: 59 +/- 15 years) were selected from the samples recruited in Belfast and Glasgow. All participants were of European descent and gave an informed consent.
###end p 10
###begin p 11
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The Athero<italic>Gene</italic> study</bold>
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 931 932 929 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1073 1074 1071 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1483 1490 1479 1486 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1563 1573 1559 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AtheroGene</italic>
###xml 1490 1702 1486 1698 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="12">Baseline characteristics of patients with coronary artery disease in the <italic>AtheroGene</italic> study according to occurrence of cardiovascular event (cardiovascular death or non-fatal myocardial infarction) during follow-up</p>
###xml 1490 1702 1486 1698 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="12">Baseline characteristics of patients with coronary artery disease in the <italic>AtheroGene</italic> study according to occurrence of cardiovascular event (cardiovascular death or non-fatal myocardial infarction) during follow-up</p></caption>
###xml 1702 1702 1698 1698 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"/>
###xml 1702 1722 1698 1718 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Cardiovascular event</th>
###xml 1702 1722 1698 1718 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2"/><th colspan="3">Cardiovascular event</th></tr>
###xml 1726 1727 1722 1723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1722 1736 1718 1732 <th xmlns:xlink="http://www.w3.org/1999/xlink">No (<italic>n</italic>&#8201;=&#8201;1,039)</th>
###xml 1741 1742 1737 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1736 1749 1732 1745 <th xmlns:xlink="http://www.w3.org/1999/xlink">Yes (<italic>n</italic>&#8201;=&#8201;235)</th>
###xml 1749 1750 1745 1746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1749 1756 1745 1752 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 1722 1756 1718 1752 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>No (<italic>n</italic>&#8201;=&#8201;1,039)</th><th>Yes (<italic>n</italic>&#8201;=&#8201;235)</th><th><italic>p</italic> value</th></tr>
###xml 1702 1756 1698 1752 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2"/><th colspan="3">Cardiovascular event</th></tr><tr><th>No (<italic>n</italic>&#8201;=&#8201;1,039)</th><th>Yes (<italic>n</italic>&#8201;=&#8201;235)</th><th><italic>p</italic> value</th></tr></thead>
###xml 1756 1766 1752 1762 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age, years</td>
###xml 1766 1776 1762 1772 <td xmlns:xlink="http://www.w3.org/1999/xlink">61.0 (0.3)</td>
###xml 1776 1786 1772 1782 <td xmlns:xlink="http://www.w3.org/1999/xlink">63.8 (0.6)</td>
###xml 1786 1793 1782 1789 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&lt;0.0001</td>
###xml 1756 1793 1752 1789 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age, years</td><td>61.0 (0.3)</td><td>63.8 (0.6)</td><td char="." align="char">&lt;0.0001</td></tr>
###xml 1793 1803 1789 1799 <td xmlns:xlink="http://www.w3.org/1999/xlink">Females, %</td>
###xml 1803 1807 1799 1803 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.1</td>
###xml 1807 1811 1803 1807 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.5</td>
###xml 1811 1815 1807 1811 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.90</td>
###xml 1793 1815 1789 1811 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Females, %</td><td>25.1</td><td>25.5</td><td char="." align="char">0.90</td></tr>
###xml 1815 1830 1811 1826 <td xmlns:xlink="http://www.w3.org/1999/xlink">Body mass index</td>
###xml 1830 1840 1826 1836 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.2 (0.1)</td>
###xml 1840 1850 1836 1846 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.3 (0.2)</td>
###xml 1850 1854 1846 1850 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.68</td>
###xml 1815 1854 1811 1850 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Body mass index</td><td>27.2 (0.1)</td><td>27.3 (0.2)</td><td char="." align="char">0.68</td></tr>
###xml 1854 1871 1850 1867 <td xmlns:xlink="http://www.w3.org/1999/xlink">Current smoker, %</td>
###xml 1871 1875 1867 1871 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.3</td>
###xml 1875 1879 1871 1875 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.6</td>
###xml 1879 1883 1875 1879 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.08</td>
###xml 1854 1883 1850 1879 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Current smoker, %</td><td>12.3</td><td>16.6</td><td char="." align="char">0.08</td></tr>
###xml 1883 1894 1879 1890 <td xmlns:xlink="http://www.w3.org/1999/xlink">Diabetes, %</td>
###xml 1894 1898 1890 1894 <td xmlns:xlink="http://www.w3.org/1999/xlink">14.6</td>
###xml 1898 1902 1894 1898 <td xmlns:xlink="http://www.w3.org/1999/xlink">22.1</td>
###xml 1902 1907 1898 1903 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.005</td>
###xml 1883 1907 1879 1903 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Diabetes, %</td><td>14.6</td><td>22.1</td><td char="." align="char">0.005</td></tr>
###xml 1907 1922 1903 1918 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hypertension, %</td>
###xml 1922 1926 1918 1922 <td xmlns:xlink="http://www.w3.org/1999/xlink">72.6</td>
###xml 1926 1930 1922 1926 <td xmlns:xlink="http://www.w3.org/1999/xlink">74.0</td>
###xml 1930 1934 1926 1930 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.65</td>
###xml 1907 1934 1903 1930 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hypertension, %</td><td>72.6</td><td>74.0</td><td char="." align="char">0.65</td></tr>
###xml 1934 1943 1930 1939 <td xmlns:xlink="http://www.w3.org/1999/xlink">Statin, %</td>
###xml 1943 1947 1939 1943 <td xmlns:xlink="http://www.w3.org/1999/xlink">36.5</td>
###xml 1947 1951 1943 1947 <td xmlns:xlink="http://www.w3.org/1999/xlink">29.4</td>
###xml 1951 1955 1947 1951 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 1934 1955 1930 1951 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Statin, %</td><td>36.5</td><td>29.4</td><td char="." align="char">0.04</td></tr>
###xml 1955 1970 1951 1966 <td xmlns:xlink="http://www.w3.org/1999/xlink">Beta-blocker, %</td>
###xml 1970 1974 1966 1970 <td xmlns:xlink="http://www.w3.org/1999/xlink">59.9</td>
###xml 1974 1978 1970 1974 <td xmlns:xlink="http://www.w3.org/1999/xlink">54.5</td>
###xml 1978 1982 1974 1978 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.13</td>
###xml 1955 1982 1951 1978 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Beta-blocker, %</td><td>59.9</td><td>54.5</td><td char="." align="char">0.13</td></tr>
###xml 1982 2025 1978 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink">Angiotensin-converting enzyme inhibitors, %</td>
###xml 2025 2029 2021 2025 <td xmlns:xlink="http://www.w3.org/1999/xlink">45.9</td>
###xml 2029 2033 2025 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink">53.2</td>
###xml 2033 2037 2029 2033 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 1982 2037 1978 2033 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Angiotensin-converting enzyme inhibitors, %</td><td>45.9</td><td>53.2</td><td char="." align="char">0.04</td></tr>
###xml 2037 2061 2033 2057 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total cholesterol, mg/dL</td>
###xml 2061 2072 2057 2068 <td xmlns:xlink="http://www.w3.org/1999/xlink">220.9 (1.4)</td>
###xml 2072 2083 2068 2079 <td xmlns:xlink="http://www.w3.org/1999/xlink">214.5 (2.9)</td>
###xml 2083 2087 2079 2083 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.05</td>
###xml 2037 2087 2033 2083 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total cholesterol, mg/dL</td><td>220.9 (1.4)</td><td>214.5 (2.9)</td><td char="." align="char">0.05</td></tr>
###xml 2087 2109 2083 2105 <td xmlns:xlink="http://www.w3.org/1999/xlink">LDL cholesterol, mg/dL</td>
###xml 2109 2120 2105 2116 <td xmlns:xlink="http://www.w3.org/1999/xlink">141.6 (1.2)</td>
###xml 2120 2131 2116 2127 <td xmlns:xlink="http://www.w3.org/1999/xlink">138.3 (2.6)</td>
###xml 2131 2135 2127 2131 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.27</td>
###xml 2087 2135 2083 2131 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LDL cholesterol, mg/dL</td><td>141.6 (1.2)</td><td>138.3 (2.6)</td><td char="." align="char">0.27</td></tr>
###xml 2135 2157 2131 2153 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL cholesterol, mg/dL</td>
###xml 2157 2167 2153 2163 <td xmlns:xlink="http://www.w3.org/1999/xlink">49.0 (0.4)</td>
###xml 2167 2177 2163 2173 <td xmlns:xlink="http://www.w3.org/1999/xlink">45.1 (0.9)</td>
###xml 2177 2183 2173 2179 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0002</td>
###xml 2135 2183 2131 2179 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL cholesterol, mg/dL</td><td>49.0 (0.4)</td><td>45.1 (0.9)</td><td char="." align="char">0.0002</td></tr>
###xml 2202 2203 2198 2199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2183 2203 2179 2199 <td xmlns:xlink="http://www.w3.org/1999/xlink">Triglyceride, mg/dL<sup>a</sup></td>
###xml 2203 2214 2199 2210 <td xmlns:xlink="http://www.w3.org/1999/xlink">167.8 (3.2)</td>
###xml 2214 2225 2210 2221 <td xmlns:xlink="http://www.w3.org/1999/xlink">172.7 (6.9)</td>
###xml 2225 2229 2221 2225 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.15</td>
###xml 2183 2229 2179 2225 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Triglyceride, mg/dL<sup>a</sup></td><td>167.8 (3.2)</td><td>172.7 (6.9)</td><td char="." align="char">0.15</td></tr>
###xml 2246 2247 2242 2243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2229 2247 2225 2243 <td xmlns:xlink="http://www.w3.org/1999/xlink">Fibrinogen, mg/dL<sup>a</sup></td>
###xml 2247 2258 2243 2254 <td xmlns:xlink="http://www.w3.org/1999/xlink">354.2 (3.8)</td>
###xml 2258 2269 2254 2265 <td xmlns:xlink="http://www.w3.org/1999/xlink">386.1 (8.0)</td>
###xml 2269 2275 2265 2271 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0002</td>
###xml 2229 2275 2225 2271 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Fibrinogen, mg/dL<sup>a</sup></td><td>354.2 (3.8)</td><td>386.1 (8.0)</td><td char="." align="char">0.0002</td></tr>
###xml 2287 2288 2283 2284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2275 2288 2271 2284 <td xmlns:xlink="http://www.w3.org/1999/xlink">hs-CRP, mg/L<sup>a</sup></td>
###xml 2288 2298 2284 2294 <td xmlns:xlink="http://www.w3.org/1999/xlink">13.8 (1.0)</td>
###xml 2298 2308 2294 2304 <td xmlns:xlink="http://www.w3.org/1999/xlink">19.5 (2.1)</td>
###xml 2308 2312 2304 2308 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.01</td>
###xml 2275 2312 2271 2308 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>hs-CRP, mg/L<sup>a</sup></td><td>13.8 (1.0)</td><td>19.5 (2.1)</td><td char="." align="char">0.01</td></tr>
###xml 1756 2312 1752 2308 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age, years</td><td>61.0 (0.3)</td><td>63.8 (0.6)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>Females, %</td><td>25.1</td><td>25.5</td><td char="." align="char">0.90</td></tr><tr><td>Body mass index</td><td>27.2 (0.1)</td><td>27.3 (0.2)</td><td char="." align="char">0.68</td></tr><tr><td>Current smoker, %</td><td>12.3</td><td>16.6</td><td char="." align="char">0.08</td></tr><tr><td>Diabetes, %</td><td>14.6</td><td>22.1</td><td char="." align="char">0.005</td></tr><tr><td>Hypertension, %</td><td>72.6</td><td>74.0</td><td char="." align="char">0.65</td></tr><tr><td>Statin, %</td><td>36.5</td><td>29.4</td><td char="." align="char">0.04</td></tr><tr><td>Beta-blocker, %</td><td>59.9</td><td>54.5</td><td char="." align="char">0.13</td></tr><tr><td>Angiotensin-converting enzyme inhibitors, %</td><td>45.9</td><td>53.2</td><td char="." align="char">0.04</td></tr><tr><td>Total cholesterol, mg/dL</td><td>220.9 (1.4)</td><td>214.5 (2.9)</td><td char="." align="char">0.05</td></tr><tr><td>LDL cholesterol, mg/dL</td><td>141.6 (1.2)</td><td>138.3 (2.6)</td><td char="." align="char">0.27</td></tr><tr><td>HDL cholesterol, mg/dL</td><td>49.0 (0.4)</td><td>45.1 (0.9)</td><td char="." align="char">0.0002</td></tr><tr><td>Triglyceride, mg/dL<sup>a</sup></td><td>167.8 (3.2)</td><td>172.7 (6.9)</td><td char="." align="char">0.15</td></tr><tr><td>Fibrinogen, mg/dL<sup>a</sup></td><td>354.2 (3.8)</td><td>386.1 (8.0)</td><td char="." align="char">0.0002</td></tr><tr><td>hs-CRP, mg/L<sup>a</sup></td><td>13.8 (1.0)</td><td>19.5 (2.1)</td><td char="." align="char">0.01</td></tr></tbody>
###xml 1702 2312 1698 2308 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Cardiovascular event</th></tr><tr><th>No (<italic>n</italic>&#8201;=&#8201;1,039)</th><th>Yes (<italic>n</italic>&#8201;=&#8201;235)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Age, years</td><td>61.0 (0.3)</td><td>63.8 (0.6)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>Females, %</td><td>25.1</td><td>25.5</td><td char="." align="char">0.90</td></tr><tr><td>Body mass index</td><td>27.2 (0.1)</td><td>27.3 (0.2)</td><td char="." align="char">0.68</td></tr><tr><td>Current smoker, %</td><td>12.3</td><td>16.6</td><td char="." align="char">0.08</td></tr><tr><td>Diabetes, %</td><td>14.6</td><td>22.1</td><td char="." align="char">0.005</td></tr><tr><td>Hypertension, %</td><td>72.6</td><td>74.0</td><td char="." align="char">0.65</td></tr><tr><td>Statin, %</td><td>36.5</td><td>29.4</td><td char="." align="char">0.04</td></tr><tr><td>Beta-blocker, %</td><td>59.9</td><td>54.5</td><td char="." align="char">0.13</td></tr><tr><td>Angiotensin-converting enzyme inhibitors, %</td><td>45.9</td><td>53.2</td><td char="." align="char">0.04</td></tr><tr><td>Total cholesterol, mg/dL</td><td>220.9 (1.4)</td><td>214.5 (2.9)</td><td char="." align="char">0.05</td></tr><tr><td>LDL cholesterol, mg/dL</td><td>141.6 (1.2)</td><td>138.3 (2.6)</td><td char="." align="char">0.27</td></tr><tr><td>HDL cholesterol, mg/dL</td><td>49.0 (0.4)</td><td>45.1 (0.9)</td><td char="." align="char">0.0002</td></tr><tr><td>Triglyceride, mg/dL<sup>a</sup></td><td>167.8 (3.2)</td><td>172.7 (6.9)</td><td char="." align="char">0.15</td></tr><tr><td>Fibrinogen, mg/dL<sup>a</sup></td><td>354.2 (3.8)</td><td>386.1 (8.0)</td><td char="." align="char">0.0002</td></tr><tr><td>hs-CRP, mg/L<sup>a</sup></td><td>13.8 (1.0)</td><td>19.5 (2.1)</td><td char="." align="char">0.01</td></tr></tbody></table>
###xml 2312 2434 2308 2430 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="13">Categorical variables are presented as percentages; continuous variables are presented as age- and sex-adjusted mean (SEM)</p>
###xml 2434 2435 2430 2431 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 2434 2477 2430 2473 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="14"><sup>a</sup>Test performed on log-transformed variable</p>
###xml 2312 2477 2308 2473 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="13">Categorical variables are presented as percentages; continuous variables are presented as age- and sex-adjusted mean (SEM)</p><p textid="14"><sup>a</sup>Test performed on log-transformed variable</p></table-wrap-foot>
###xml 1483 2477 1479 2473 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="12">Baseline characteristics of patients with coronary artery disease in the <italic>AtheroGene</italic> study according to occurrence of cardiovascular event (cardiovascular death or non-fatal myocardial infarction) during follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="3">Cardiovascular event</th></tr><tr><th>No (<italic>n</italic>&#8201;=&#8201;1,039)</th><th>Yes (<italic>n</italic>&#8201;=&#8201;235)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Age, years</td><td>61.0 (0.3)</td><td>63.8 (0.6)</td><td char="." align="char">&lt;0.0001</td></tr><tr><td>Females, %</td><td>25.1</td><td>25.5</td><td char="." align="char">0.90</td></tr><tr><td>Body mass index</td><td>27.2 (0.1)</td><td>27.3 (0.2)</td><td char="." align="char">0.68</td></tr><tr><td>Current smoker, %</td><td>12.3</td><td>16.6</td><td char="." align="char">0.08</td></tr><tr><td>Diabetes, %</td><td>14.6</td><td>22.1</td><td char="." align="char">0.005</td></tr><tr><td>Hypertension, %</td><td>72.6</td><td>74.0</td><td char="." align="char">0.65</td></tr><tr><td>Statin, %</td><td>36.5</td><td>29.4</td><td char="." align="char">0.04</td></tr><tr><td>Beta-blocker, %</td><td>59.9</td><td>54.5</td><td char="." align="char">0.13</td></tr><tr><td>Angiotensin-converting enzyme inhibitors, %</td><td>45.9</td><td>53.2</td><td char="." align="char">0.04</td></tr><tr><td>Total cholesterol, mg/dL</td><td>220.9 (1.4)</td><td>214.5 (2.9)</td><td char="." align="char">0.05</td></tr><tr><td>LDL cholesterol, mg/dL</td><td>141.6 (1.2)</td><td>138.3 (2.6)</td><td char="." align="char">0.27</td></tr><tr><td>HDL cholesterol, mg/dL</td><td>49.0 (0.4)</td><td>45.1 (0.9)</td><td char="." align="char">0.0002</td></tr><tr><td>Triglyceride, mg/dL<sup>a</sup></td><td>167.8 (3.2)</td><td>172.7 (6.9)</td><td char="." align="char">0.15</td></tr><tr><td>Fibrinogen, mg/dL<sup>a</sup></td><td>354.2 (3.8)</td><td>386.1 (8.0)</td><td char="." align="char">0.0002</td></tr><tr><td>hs-CRP, mg/L<sup>a</sup></td><td>13.8 (1.0)</td><td>19.5 (2.1)</td><td char="." align="char">0.01</td></tr></tbody></table><table-wrap-foot><p textid="13">Categorical variables are presented as percentages; continuous variables are presented as age- and sex-adjusted mean (SEM)</p><p textid="14"><sup>a</sup>Test performed on log-transformed variable</p></table-wrap-foot></table-wrap>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 776 784 <span type="species:ncbi:9606">Patients</span>
###xml 1252 1264 <span type="species:ncbi:9606">participants</span>
###xml 1440 1451 <span type="species:ncbi:9606">participant</span>
###xml 1518 1526 <span type="species:ncbi:9606">patients</span>
The AtheroGene study Baseline characteristics are provided in Table 1; whereas, detailed description of the study has been provided elsewhere [20, 21]. Briefly, between November 1996 and June 2000, 1,303 CAD patients (75% males, mean age: 61.7 +/- 0.3 years) were recruited at the Department of Medicine II of the Johannes Gutenberg University Mainz and the Bundeswehrzentralkrankenhaus Koblenz at the occasion of a diagnostic coronary angiography. A priori inclusion criterion was the presence of a diameter stenosis >30% in at least one major coronary artery. Exclusion criteria were evidence of significant concomitant diseases, in particular, hemodynamically significant valvular heart disease, known cardiomyopathy, and malignant diseases, as well as febrile conditions. Patients were followed-up during a median period of 6.2 years. Follow-up information was obtained about death from cardiovascular causes and non-fatal MI (n = 235). Information about the cause of death or clinical events was obtained by hospital or general practitioner. Healthy control subjects (n = 484, 73% males, mean age 60.0 +/- 0.4 years) were recruited either from general practitioners' offices in the course of a routine check-up or by newspaper announcement. Study participants had German nationality, were inhabitants of the Rhein-Main area, and were of Caucasian origin. The study was approved by the ethics committee of the University of Mainz. Each participant gave written informed consent. Table 1Baseline characteristics of patients with coronary artery disease in the AtheroGene study according to occurrence of cardiovascular event (cardiovascular death or non-fatal myocardial infarction) during follow-upCardiovascular eventNo (n = 1,039)Yes (n = 235)p valueAge, years61.0 (0.3)63.8 (0.6)<0.0001Females, %25.125.50.90Body mass index27.2 (0.1)27.3 (0.2)0.68Current smoker, %12.316.60.08Diabetes, %14.622.10.005Hypertension, %72.674.00.65Statin, %36.529.40.04Beta-blocker, %59.954.50.13Angiotensin-converting enzyme inhibitors, %45.953.20.04Total cholesterol, mg/dL220.9 (1.4)214.5 (2.9)0.05LDL cholesterol, mg/dL141.6 (1.2)138.3 (2.6)0.27HDL cholesterol, mg/dL49.0 (0.4)45.1 (0.9)0.0002Triglyceride, mg/dLa167.8 (3.2)172.7 (6.9)0.15Fibrinogen, mg/dLa354.2 (3.8)386.1 (8.0)0.0002hs-CRP, mg/La13.8 (1.0)19.5 (2.1)0.01Categorical variables are presented as percentages; continuous variables are presented as age- and sex-adjusted mean (SEM)aTest performed on log-transformed variable
###end p 11
###begin p 12
###xml 73 83 73 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AtheroGene</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Baseline characteristics of patients with coronary artery disease in the AtheroGene study according to occurrence of cardiovascular event (cardiovascular death or non-fatal myocardial infarction) during follow-up
###end p 12
###begin p 13
Categorical variables are presented as percentages; continuous variables are presented as age- and sex-adjusted mean (SEM)
###end p 13
###begin p 14
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aTest performed on log-transformed variable
###end p 14
###begin title 15
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
Molecular screening of the PLA2G10 gene and genotyping of the polymorphisms
###end title 15
###begin p 16
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 833 840 833 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
We screened the PLA2G10 gene using the genomic sequences retrieved from public depositories. The screening of the gene was performed using genomic DNA from 62 unrelated MI patients selected from the ECTIM study (). Using polymerase chain reaction (PCR) and direct sequencing, we explored 1 kb of the promoter, the entire exonic sequences with their corresponding flanking intronic sequences, and 1 kb of the 3' region after the codon stop. The sequences were aligned and analyzed with the SeqScape software (Applied Biosystems) to determine the potential polymorphisms. The genotyping of the polymorphisms was performed using a modified PCR-restriction fragment length polymorphism method or the TaqMan (5' nuclease assay) technology. The description of polymorphisms and genotyping conditions can be found at our web site (, genes: PLA2G10).
###end p 16
###begin title 17
Statistical analysis
###end title 17
###begin p 18
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 117 119 117 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 355 357 355 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Differences in genotype frequencies between cases and controls were tested by a Chi2 test with 2 degrees of freedom (df), adjusted for center in the SIPLAC study (Mantel-Haenszel test). Allele frequencies were deduced from genotype frequencies. Departure from Hardy-Weinberg equilibrium was tested for each polymorphism in controls by Chi2 testing with 1 df. P values < 0.05 were taken as significant.
###end p 18
###begin p 19
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
LD and haplotype analyses were performed using the Testing Haplotype EffectS In Association Studies (THESIAS) program available online () [22]. Differences in haplotypic frequency distributions between cases and controls in the AtheroGene study were tested by means of the likelihood ratio test. Associations between polymorphisms and cardiovascular risk factors (lipids and inflammatory markers) were tested by a general linear model adjusted for age and sex. Association of genotypes with prospective cardiovascular outcome was tested by a Cox proportional hazards regression analysis adjusted for age and sex.
###end p 19
###begin title 20
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
Functional analysis of the PLA2G10/R38C polymorphism
###end title 20
###begin title 21
DNA construct
###end title 21
###begin p 22
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAATTC</italic>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATATC</italic>
###xml 451 460 451 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AGCGGCCGC</italic>
###xml 460 463 460 463 <underline xmlns:xlink="http://www.w3.org/1999/xlink">TCA</underline>
###xml 463 490 463 490 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AGCGTAATCTGGAACATCGTATGGGTA</bold>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GATATC</italic>
###xml 7 12 <span type="species:ncbi:9606">human</span>
###xml 243 248 <span type="species:ncbi:9606">human</span>
Active human GX sPLA2 complementary DNA (cDNA) starting at the second methionine initiator site, containing additional nucleotide sequences for expressing the hemagglutinin epitope tag (HA tag, nine amino acids YPYDVPDYA) at the C terminus of human GX sPLA2 protein, were generated by PCR, using the forward oligonucleotide (5'_TGTCGAATTCTGCAGATATCCCGCCATGCTGCTCCTGCTACTGCC_3') with EcoRI and EcoRV sites (italics), and reverse oligonucleotide (5'_CTTAGCGGCCGCTCAAGCGTAATCTGGAACATCGTATGGGTAGATATCGTCACACTTGGGCGAGTC_3') with EcoRI and NotI sites (italics), stop codon (underlined), and additional nucleotide sequences (bold) coding for the HA tag sequence. The amplified fragments were purified, digested with EcoRI and NotI, and inserted into the EcoRI and NotI sites of pcDNA3 vector to generate the expression plasmid pcDNA-hGX-HA. All constructs were confirmed by sequencing. Inserting the HA tag at the C terminus of hGX sPLA2 protein has no effect on hGX sPLA2 activity (data not shown).
###end p 22
###begin title 23
Site-directed mutagenesis
###end title 23
###begin p 24
###xml 240 241 240 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink">t</bold>
###xml 652 668 648 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 652 668 <span type="species:ncbi:562">Escherichia coli</span>
The pcDNA-hGX-HA construct was used as a template in the Quick-change site-directed mutagenesis procedure according to manufacturer's instructions. Forward mutagenic primer used to create the R38C point mutation was 5'_GGCGAGGCCTCCAGGATATTAtGTGTGCACCGGCGTGGGATCC -3'. Text in bolded lowercase represents the mismatch base introduced to obtain the desired mutation. Reverse mutagenic primer was of the same length and complementary to the forward mutagenic primer. Following amplification, the reaction mixture was treated with DpnI to eliminate the template DNA. Each of the mutated amplification products were transformed into max efficiency DH5alpha Escherichia coli strain (Invitrogen), and mutations were confirmed by DNA sequencing of the resulting constructs.
###end p 24
###begin title 25
Constructs containing the R38 or the C38 allele
###end title 25
###begin p 26
###xml 87 91 <span type="species:ncbi:9913">calf</span>
COS-7 cells were cultured in Dulbecco's modified essential medium containing 10% fetal calf serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Confluent cells (75%) were harvested with trypsin and transfected with the above-described constructs containing the R38 or C38 harboring cDNA and pmax green fluorescent protein (GFP; Amaxa) using the Cell line nucleofector kit V and Amaxa nucleofector (Amaxa Inc.) according to the manufacturer's instructions. Transfection efficiency was estimated 24 h after electroporation by fluorescence activated cell sorter analysis. The number of GFP positive cells in a sample of pmaxGFP (Amaxa)-transfected cells varied between 75% and 79%. After transfection, cells were cultured in 6-well plates for 24 h additionally at 37degreesC. Selected experiments were performed at both 37degreesC and 30degreesC.
###end p 26
###begin title 27
Time-resolved fluoroimmunoassay (TR-FIA) and phospholipase A2 activity
###end title 27
###begin p 28
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 283 290 283 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 283 290 <span type="species:ncbi:562">E. coli</span>
Cell lysates extracted in radio immunoprecipitation assay (RIPA) buffer and cell supernatants were directly used for time-resolved fluoroimmunoassays (TR-FIA) to detect hGX sPLA2 protein concentration as described [23]. hGX sPLA2 enzymatic activity was determined using radiolabeled E. coli membranes as previously described [24].
###end p 28
###begin title 29
Fluorescence immunocytochemistry and confocal microscopy
###end title 29
###begin p 30
###xml 322 328 <span type="species:ncbi:9913">bovine</span>
###xml 403 409 <span type="species:ncbi:9986">rabbit</span>
###xml 432 437 <span type="species:ncbi:10090">mouse</span>
###xml 540 545 <span type="species:ncbi:10090">mouse</span>
###xml 815 820 <span type="species:ncbi:10090">mouse</span>
###xml 842 848 <span type="species:ncbi:9986">rabbit</span>
COS-7 cells were transiently transfected with HA-tagged either wild-type or mutant hGX sPLA2 as described below. 24 h after transfection, the phosphate buffer solution (PBS)-washed cells were fixed in 4% paraformaldehyde. Cells were permeabilized with methanol for 10 min. Washed cells were incubated in PBS containing 1% bovine serum albumin (BSA; PBS/BSA) for 1 h. Incubation with primary antibodies (rabbit polyclonal hGX sPLA2, mouse monoclonal protein disulphide isomerase (PDI; Stressgen) for endoplasmic reticulum (ER) staining, and mouse monoclonal Golgi 58 K protein (Sigma) for Golgi apparatus) were carried out in PBS/BSA for 1 h at reverse transcription (RT). Cover slips were subsequently washed four times in PBS/BSA and incubated with secondary antibodies (fluorescein isothiocyanate-conjugated anti-mouse, Cy5-conjugated anti-rabbit (Dako)) and 4'-6-diamidino-2-phenylindole (DAPI; 0.5 mg/ml) for 1 h at RT. Cover slips were washed in PBS and mounted in Moviol. Confocal analysis was performed on a Leica SP2-AOBS confocal microscope, and the images were taken using alternating mode to minimize the channel interference (Leica confocal software).
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
Screening of the gene
###end title 32
###begin p 33
###xml 24 31 24 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 642 649 642 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 652 658 652 658 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 696 703 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 754 767 754 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical bars</italic>
###xml 934 938 934 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 658 938 658 938 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Schematic representation of the human <italic>PLA2G10</italic> gene and the position of SNPs. Exons are shown as <italic>vertical bars</italic>. Intron size is indicated. Exons 1&#8211;4 encode for the 123 amino acid hGX sPLA2 protein. The polymorphism that resulted in arginine to cysteine substitution is shown in <italic>bold</italic></p>
###xml 658 938 658 938 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Schematic representation of the human <italic>PLA2G10</italic> gene and the position of SNPs. Exons are shown as <italic>vertical bars</italic>. Intron size is indicated. Exons 1&#8211;4 encode for the 123 amino acid hGX sPLA2 protein. The polymorphism that resulted in arginine to cysteine substitution is shown in <italic>bold</italic></p></caption>
###xml 938 938 938 938 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2009_483_Fig1_HTML" id="MO1"/>
###xml 652 938 652 938 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="34">Schematic representation of the human <italic>PLA2G10</italic> gene and the position of SNPs. Exons are shown as <italic>vertical bars</italic>. Intron size is indicated. Exons 1&#8211;4 encode for the 123 amino acid hGX sPLA2 protein. The polymorphism that resulted in arginine to cysteine substitution is shown in <italic>bold</italic></p></caption><graphic position="anchor" xlink:href="109_2009_483_Fig1_HTML" id="MO1"/></fig>
###xml 938 945 938 945 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 977 984 977 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 945 1005 945 1005 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Polymorphisms identified in the <italic>PLA2G10</italic> gene (chromosome 16)</p>
###xml 945 1005 945 1005 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Polymorphisms identified in the <italic>PLA2G10</italic> gene (chromosome 16)</p></caption>
###xml 1005 1017 1005 1017 <th xmlns:xlink="http://www.w3.org/1999/xlink">Polymorphism</th>
###xml 1017 1023 1017 1023 <th xmlns:xlink="http://www.w3.org/1999/xlink">SNP ID</th>
###xml 1023 1058 1023 1058 <th xmlns:xlink="http://www.w3.org/1999/xlink">Base substitution on reverse strand</th>
###xml 1058 1071 1058 1071 <th xmlns:xlink="http://www.w3.org/1999/xlink">Gene location</th>
###xml 1071 1091 1071 1091 <th xmlns:xlink="http://www.w3.org/1999/xlink">Chromosomal position</th>
###xml 1005 1091 1005 1091 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Polymorphism</th><th>SNP ID</th><th>Base substitution on reverse strand</th><th>Gene location</th><th>Chromosomal position</th></tr>
###xml 1005 1091 1005 1091 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Polymorphism</th><th>SNP ID</th><th>Base substitution on reverse strand</th><th>Gene location</th><th>Chromosomal position</th></tr></thead>
###xml 1091 1097 1091 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink">T-512C</td>
###xml 1097 1109 1097 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink">ss#115456686</td>
###xml 1109 1112 1109 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink">T/c</td>
###xml 1112 1114 1112 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink">5&#8242;</td>
###xml 1114 1122 1114 1122 <td xmlns:xlink="http://www.w3.org/1999/xlink">14696099</td>
###xml 1091 1122 1091 1122 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T-512C</td><td>ss#115456686</td><td>T/c</td><td>5&#8242;</td><td>14696099</td></tr>
###xml 1122 1132 1122 1132 <td xmlns:xlink="http://www.w3.org/1999/xlink">T-123/in1C</td>
###xml 1132 1142 1132 1142 <td xmlns:xlink="http://www.w3.org/1999/xlink">rs#4003232</td>
###xml 1142 1145 1142 1145 <td xmlns:xlink="http://www.w3.org/1999/xlink">T/c</td>
###xml 1145 1153 1145 1153 <td xmlns:xlink="http://www.w3.org/1999/xlink">Intron 1</td>
###xml 1153 1161 1153 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink">14692126</td>
###xml 1122 1161 1122 1161 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T-123/in1C</td><td>rs#4003232</td><td>T/c</td><td>Intron 1</td><td>14692126</td></tr>
###xml 1170 1171 1170 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1161 1171 1161 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink">C-85/in1T<sup>a</sup></td>
###xml 1171 1182 1171 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink">rs#35822154</td>
###xml 1182 1185 1182 1185 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/t</td>
###xml 1185 1193 1185 1193 <td xmlns:xlink="http://www.w3.org/1999/xlink">Intron 1</td>
###xml 1193 1201 1193 1201 <td xmlns:xlink="http://www.w3.org/1999/xlink">14692088</td>
###xml 1161 1201 1161 1201 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>C-85/in1T<sup>a</sup></td><td>rs#35822154</td><td>C/t</td><td>Intron 1</td><td>14692088</td></tr>
###xml 1201 1210 1201 1210 <td xmlns:xlink="http://www.w3.org/1999/xlink">G-80/in1A</td>
###xml 1210 1221 1210 1221 <td xmlns:xlink="http://www.w3.org/1999/xlink">rs#34782548</td>
###xml 1221 1224 1221 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink">G/a</td>
###xml 1224 1232 1224 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink">Intron 1</td>
###xml 1232 1240 1232 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink">14692083</td>
###xml 1201 1240 1201 1240 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>G-80/in1A</td><td>rs#34782548</td><td>G/a</td><td>Intron 1</td><td>14692083</td></tr>
###xml 1240 1244 1240 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink">R38C</td>
###xml 1244 1254 1244 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink">rs#4003228</td>
###xml 1254 1257 1254 1257 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/t</td>
###xml 1257 1263 1257 1263 <td xmlns:xlink="http://www.w3.org/1999/xlink">Exon 2</td>
###xml 1263 1271 1263 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink">14691989</td>
###xml 1240 1271 1240 1271 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>R38C</td><td>rs#4003228</td><td>C/t</td><td>Exon 2</td><td>14691989</td></tr>
###xml 1271 1277 1271 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink">C+264A</td>
###xml 1277 1289 1277 1289 <td xmlns:xlink="http://www.w3.org/1999/xlink">ss#105111473</td>
###xml 1289 1292 1289 1292 <td xmlns:xlink="http://www.w3.org/1999/xlink">C/a</td>
###xml 1292 1294 1292 1294 <td xmlns:xlink="http://www.w3.org/1999/xlink">3&#8242;</td>
###xml 1294 1302 1294 1302 <td xmlns:xlink="http://www.w3.org/1999/xlink">14673705</td>
###xml 1271 1302 1271 1302 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>C+264A</td><td>ss#105111473</td><td>C/a</td><td>3&#8242;</td><td>14673705</td></tr>
###xml 1302 1308 1302 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink">G+303C</td>
###xml 1308 1320 1308 1320 <td xmlns:xlink="http://www.w3.org/1999/xlink">ss#105111474</td>
###xml 1320 1323 1320 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink">G/c</td>
###xml 1323 1325 1323 1325 <td xmlns:xlink="http://www.w3.org/1999/xlink">3&#8242;</td>
###xml 1325 1333 1325 1333 <td xmlns:xlink="http://www.w3.org/1999/xlink">14673666</td>
###xml 1302 1333 1302 1333 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>G+303C</td><td>ss#105111474</td><td>G/c</td><td>3&#8242;</td><td>14673666</td></tr>
###xml 1333 1339 1333 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink">T+659C</td>
###xml 1339 1351 1339 1351 <td xmlns:xlink="http://www.w3.org/1999/xlink">ss#105111475</td>
###xml 1351 1354 1351 1354 <td xmlns:xlink="http://www.w3.org/1999/xlink">T/c</td>
###xml 1354 1356 1354 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink">3&#8242;</td>
###xml 1356 1364 1356 1364 <td xmlns:xlink="http://www.w3.org/1999/xlink">14673310</td>
###xml 1333 1364 1333 1364 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T+659C</td><td>ss#105111475</td><td>T/c</td><td>3&#8242;</td><td>14673310</td></tr>
###xml 1091 1364 1091 1364 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>T-512C</td><td>ss#115456686</td><td>T/c</td><td>5&#8242;</td><td>14696099</td></tr><tr><td>T-123/in1C</td><td>rs#4003232</td><td>T/c</td><td>Intron 1</td><td>14692126</td></tr><tr><td>C-85/in1T<sup>a</sup></td><td>rs#35822154</td><td>C/t</td><td>Intron 1</td><td>14692088</td></tr><tr><td>G-80/in1A</td><td>rs#34782548</td><td>G/a</td><td>Intron 1</td><td>14692083</td></tr><tr><td>R38C</td><td>rs#4003228</td><td>C/t</td><td>Exon 2</td><td>14691989</td></tr><tr><td>C+264A</td><td>ss#105111473</td><td>C/a</td><td>3&#8242;</td><td>14673705</td></tr><tr><td>G+303C</td><td>ss#105111474</td><td>G/c</td><td>3&#8242;</td><td>14673666</td></tr><tr><td>T+659C</td><td>ss#105111475</td><td>T/c</td><td>3&#8242;</td><td>14673310</td></tr></tbody>
###xml 1005 1364 1005 1364 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Polymorphism</th><th>SNP ID</th><th>Base substitution on reverse strand</th><th>Gene location</th><th>Chromosomal position</th></tr></thead><tbody><tr><td>T-512C</td><td>ss#115456686</td><td>T/c</td><td>5&#8242;</td><td>14696099</td></tr><tr><td>T-123/in1C</td><td>rs#4003232</td><td>T/c</td><td>Intron 1</td><td>14692126</td></tr><tr><td>C-85/in1T<sup>a</sup></td><td>rs#35822154</td><td>C/t</td><td>Intron 1</td><td>14692088</td></tr><tr><td>G-80/in1A</td><td>rs#34782548</td><td>G/a</td><td>Intron 1</td><td>14692083</td></tr><tr><td>R38C</td><td>rs#4003228</td><td>C/t</td><td>Exon 2</td><td>14691989</td></tr><tr><td>C+264A</td><td>ss#105111473</td><td>C/a</td><td>3&#8242;</td><td>14673705</td></tr><tr><td>G+303C</td><td>ss#105111474</td><td>G/c</td><td>3&#8242;</td><td>14673666</td></tr><tr><td>T+659C</td><td>ss#105111475</td><td>T/c</td><td>3&#8242;</td><td>14673310</td></tr></tbody></table>
###xml 1364 1365 1364 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1364 1410 1364 1410 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><sup>a</sup>Not genotyped owing to technical difficulties</p>
###xml 1364 1410 1364 1410 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><sup>a</sup>Not genotyped owing to technical difficulties</p></table-wrap-foot>
###xml 938 1410 938 1410 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="35">Polymorphisms identified in the <italic>PLA2G10</italic> gene (chromosome 16)</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Polymorphism</th><th>SNP ID</th><th>Base substitution on reverse strand</th><th>Gene location</th><th>Chromosomal position</th></tr></thead><tbody><tr><td>T-512C</td><td>ss#115456686</td><td>T/c</td><td>5&#8242;</td><td>14696099</td></tr><tr><td>T-123/in1C</td><td>rs#4003232</td><td>T/c</td><td>Intron 1</td><td>14692126</td></tr><tr><td>C-85/in1T<sup>a</sup></td><td>rs#35822154</td><td>C/t</td><td>Intron 1</td><td>14692088</td></tr><tr><td>G-80/in1A</td><td>rs#34782548</td><td>G/a</td><td>Intron 1</td><td>14692083</td></tr><tr><td>R38C</td><td>rs#4003228</td><td>C/t</td><td>Exon 2</td><td>14691989</td></tr><tr><td>C+264A</td><td>ss#105111473</td><td>C/a</td><td>3&#8242;</td><td>14673705</td></tr><tr><td>G+303C</td><td>ss#105111474</td><td>G/c</td><td>3&#8242;</td><td>14673666</td></tr><tr><td>T+659C</td><td>ss#105111475</td><td>T/c</td><td>3&#8242;</td><td>14673310</td></tr></tbody></table><table-wrap-foot><p textid="36"><sup>a</sup>Not genotyped owing to technical difficulties</p></table-wrap-foot></table-wrap>
###xml 690 695 <span type="species:ncbi:9606">human</span>
The organization of the PLA2G10 gene is shown in Fig. 1. It consists of four exons (537, 151, 107, and 143 bp, respectively) and three introns (3,488, 2,223, and 15,414 bp, respectively). We screened all exonic sequences with their corresponding flanking intronic sequences, as well as 1 kb in the putative promoter region and 1 kb after the stop codon. From our molecular screening in 124 chromosomes from 62 unrelated subjects, we identified eight polymorphisms (Table 2) which were first genotyped in the SIPLAC study in order to determine their allelic and haplotypic frequencies. Their description can be found at our web site (, genes: PLA2G10). Fig. 1Schematic representation of the human PLA2G10 gene and the position of SNPs. Exons are shown as vertical bars. Intron size is indicated. Exons 1-4 encode for the 123 amino acid hGX sPLA2 protein. The polymorphism that resulted in arginine to cysteine substitution is shown in boldTable 2Polymorphisms identified in the PLA2G10 gene (chromosome 16)PolymorphismSNP IDBase substitution on reverse strandGene locationChromosomal positionT-512Css#115456686T/c5'14696099T-123/in1Crs#4003232T/cIntron 114692126C-85/in1Tars#35822154C/tIntron 114692088G-80/in1Ars#34782548G/aIntron 114692083R38Crs#4003228C/tExon 214691989C+264Ass#105111473C/a3'14673705G+303Css#105111474G/c3'14673666T+659Css#105111475T/c3'14673310aNot genotyped owing to technical difficulties
###end p 33
###begin p 34
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 96 109 96 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vertical bars</italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 32 37 <span type="species:ncbi:9606">human</span>
Schematic representation of the human PLA2G10 gene and the position of SNPs. Exons are shown as vertical bars. Intron size is indicated. Exons 1-4 encode for the 123 amino acid hGX sPLA2 protein. The polymorphism that resulted in arginine to cysteine substitution is shown in bold
###end p 34
###begin p 35
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
Polymorphisms identified in the PLA2G10 gene (chromosome 16)
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNot genotyped owing to technical difficulties
###end p 36
###begin title 37
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
PLA2G10 polymorphisms in the SIPLAC study
###end title 37
###begin p 38
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 722 729 722 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 732 739 732 739 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 809 810 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 832 833 832 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 739 893 739 893 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Genotype and minor allele frequencies in myocardial infarction cases (<italic>n</italic>&#8201;=&#8201;312) and controls (<italic>n</italic>&#8201;=&#8201;317) of the SIPLAC study (Belfast and Glasgow pooled, UK)</p>
###xml 739 893 739 893 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Genotype and minor allele frequencies in myocardial infarction cases (<italic>n</italic>&#8201;=&#8201;312) and controls (<italic>n</italic>&#8201;=&#8201;317) of the SIPLAC study (Belfast and Glasgow pooled, UK)</p></caption>
###xml 893 893 893 893 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2"/>
###xml 893 915 893 915 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Genotype frequency (%)</th>
###xml 915 916 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 915 942 915 942 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value adjusted for center</th>
###xml 942 964 942 964 <th xmlns:xlink="http://www.w3.org/1999/xlink">Minor allele frequency</th>
###xml 893 964 893 964 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value adjusted for center</th><th>Minor allele frequency</th></tr>
###xml 964 964 964 964 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 964 964 964 964 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 964 966 964 966 <th xmlns:xlink="http://www.w3.org/1999/xlink">11</th>
###xml 966 968 966 968 <th xmlns:xlink="http://www.w3.org/1999/xlink">12</th>
###xml 968 970 968 970 <th xmlns:xlink="http://www.w3.org/1999/xlink">22</th>
###xml 970 970 970 970 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 970 970 970 970 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 964 970 964 970 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr>
###xml 893 970 893 970 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value adjusted for center</th><th>Minor allele frequency</th></tr><tr><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr></thead>
###xml 970 976 970 976 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">T-512C</td>
###xml 976 981 976 981 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 981 986 981 986 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36.2%</td>
###xml 986 991 986 991 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48.3%</td>
###xml 991 996 991 996 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15.5%</td>
###xml 996 996 996 996 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 996 1000 996 1000 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.40</td>
###xml 970 1000 970 1000 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">36.2%</td><td char="." align="char">48.3%</td><td char="." align="char">15.5%</td><td/><td char="." align="char">0.40</td></tr>
###xml 1000 1008 1000 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1008 1013 1008 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">41.8%</td>
###xml 1013 1018 1013 1018 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">46.6%</td>
###xml 1018 1023 1018 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11.6%</td>
###xml 1023 1027 1023 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.31</td>
###xml 1027 1031 1027 1031 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.35</td>
###xml 1000 1031 1000 1031 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">41.8%</td><td char="." align="char">46.6%</td><td char="." align="char">11.6%</td><td char="." align="char">0.31</td><td char="." align="char">0.35</td></tr>
###xml 1031 1041 1031 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">T-123/in1C</td>
###xml 1041 1046 1041 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 1046 1051 1046 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61.0%</td>
###xml 1051 1056 1051 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">34.2%</td>
###xml 1056 1060 1056 1060 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.8%</td>
###xml 1060 1060 1060 1060 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1060 1064 1060 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.22</td>
###xml 1031 1064 1031 1064 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">61.0%</td><td char="." align="char">34.2%</td><td char="." align="char">4.8%</td><td/><td char="." align="char">0.22</td></tr>
###xml 1064 1072 1064 1072 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1072 1077 1072 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.6%</td>
###xml 1077 1082 1077 1082 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">35.5%</td>
###xml 1082 1086 1082 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.9%</td>
###xml 1086 1090 1086 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.55</td>
###xml 1090 1094 1090 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.25</td>
###xml 1064 1094 1064 1094 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">57.6%</td><td char="." align="char">35.5%</td><td char="." align="char">6.9%</td><td char="." align="char">0.55</td><td char="." align="char">0.25</td></tr>
###xml 1103 1104 1103 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1094 1104 1094 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">G-80/in1A<sup>a</sup></td>
###xml 1104 1109 1104 1109 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 1109 1114 1109 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">54.9%</td>
###xml 1114 1119 1114 1119 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38.5%</td>
###xml 1119 1123 1119 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.6%</td>
###xml 1123 1123 1123 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1123 1127 1123 1127 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.26</td>
###xml 1094 1127 1094 1127 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">G-80/in1A<sup>a</sup></td><td>Cases</td><td char="." align="char">54.9%</td><td char="." align="char">38.5%</td><td char="." align="char">6.6%</td><td/><td char="." align="char">0.26</td></tr>
###xml 1127 1135 1127 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1135 1140 1135 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">49.3%</td>
###xml 1140 1145 1140 1145 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">41.5%</td>
###xml 1145 1149 1145 1149 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.2%</td>
###xml 1149 1153 1149 1153 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.40</td>
###xml 1153 1157 1153 1157 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.30</td>
###xml 1127 1157 1127 1157 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">49.3%</td><td char="." align="char">41.5%</td><td char="." align="char">9.2%</td><td char="." align="char">0.40</td><td char="." align="char">0.30</td></tr>
###xml 1157 1161 1157 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">R38C</td>
###xml 1161 1166 1161 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 1166 1171 1166 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">97.0%</td>
###xml 1171 1175 1171 1175 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.0%</td>
###xml 1175 1179 1175 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 1179 1179 1179 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1179 1183 1179 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 1157 1183 1157 1183 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">97.0%</td><td char="." align="char">3.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr>
###xml 1183 1191 1183 1191 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1191 1196 1191 1196 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">95.2%</td>
###xml 1196 1200 1196 1200 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.8%</td>
###xml 1200 1204 1200 1204 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 1204 1208 1204 1208 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.30</td>
###xml 1208 1212 1208 1212 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 1183 1212 1183 1212 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">95.2%</td><td char="." align="char">4.8%</td><td char="." align="char">0.0%</td><td char="." align="char">0.30</td><td char="." align="char">0.02</td></tr>
###xml 1212 1218 1212 1218 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">C+264A</td>
###xml 1218 1223 1218 1223 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 1223 1228 1223 1228 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">87.5%</td>
###xml 1228 1233 1228 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">12.1%</td>
###xml 1233 1237 1233 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.4%</td>
###xml 1237 1237 1237 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1237 1241 1237 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.06</td>
###xml 1212 1241 1212 1241 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">87.5%</td><td char="." align="char">12.1%</td><td char="." align="char">0.4%</td><td/><td char="." align="char">0.06</td></tr>
###xml 1241 1249 1241 1249 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1249 1254 1249 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">89.3%</td>
###xml 1254 1259 1254 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.3%</td>
###xml 1259 1263 1259 1263 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.4%</td>
###xml 1263 1267 1263 1267 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.82</td>
###xml 1267 1271 1267 1271 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.06</td>
###xml 1241 1271 1241 1271 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">89.3%</td><td char="." align="char">10.3%</td><td char="." align="char">0.4%</td><td char="." align="char">0.82</td><td char="." align="char">0.06</td></tr>
###xml 1271 1277 1271 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">G+303C</td>
###xml 1277 1282 1277 1282 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 1282 1287 1282 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">92.1%</td>
###xml 1287 1291 1287 1291 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.9%</td>
###xml 1291 1295 1291 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 1295 1295 1295 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1295 1299 1295 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 1271 1299 1271 1299 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">92.1%</td><td char="." align="char">7.9%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.04</td></tr>
###xml 1299 1307 1299 1307 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1307 1312 1307 1312 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">92.3%</td>
###xml 1312 1316 1312 1316 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.7%</td>
###xml 1316 1320 1316 1320 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 1320 1324 1320 1324 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.97</td>
###xml 1324 1328 1324 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.04</td>
###xml 1299 1328 1299 1328 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">92.3%</td><td char="." align="char">7.7%</td><td char="." align="char">0.0%</td><td char="." align="char">0.97</td><td char="." align="char">0.04</td></tr>
###xml 970 1328 970 1328 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">36.2%</td><td char="." align="char">48.3%</td><td char="." align="char">15.5%</td><td/><td char="." align="char">0.40</td></tr><tr><td>Controls</td><td char="." align="char">41.8%</td><td char="." align="char">46.6%</td><td char="." align="char">11.6%</td><td char="." align="char">0.31</td><td char="." align="char">0.35</td></tr><tr><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">61.0%</td><td char="." align="char">34.2%</td><td char="." align="char">4.8%</td><td/><td char="." align="char">0.22</td></tr><tr><td>Controls</td><td char="." align="char">57.6%</td><td char="." align="char">35.5%</td><td char="." align="char">6.9%</td><td char="." align="char">0.55</td><td char="." align="char">0.25</td></tr><tr><td rowspan="2">G-80/in1A<sup>a</sup></td><td>Cases</td><td char="." align="char">54.9%</td><td char="." align="char">38.5%</td><td char="." align="char">6.6%</td><td/><td char="." align="char">0.26</td></tr><tr><td>Controls</td><td char="." align="char">49.3%</td><td char="." align="char">41.5%</td><td char="." align="char">9.2%</td><td char="." align="char">0.40</td><td char="." align="char">0.30</td></tr><tr><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">97.0%</td><td char="." align="char">3.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">95.2%</td><td char="." align="char">4.8%</td><td char="." align="char">0.0%</td><td char="." align="char">0.30</td><td char="." align="char">0.02</td></tr><tr><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">87.5%</td><td char="." align="char">12.1%</td><td char="." align="char">0.4%</td><td/><td char="." align="char">0.06</td></tr><tr><td>Controls</td><td char="." align="char">89.3%</td><td char="." align="char">10.3%</td><td char="." align="char">0.4%</td><td char="." align="char">0.82</td><td char="." align="char">0.06</td></tr><tr><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">92.1%</td><td char="." align="char">7.9%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.04</td></tr><tr><td>Controls</td><td char="." align="char">92.3%</td><td char="." align="char">7.7%</td><td char="." align="char">0.0%</td><td char="." align="char">0.97</td><td char="." align="char">0.04</td></tr></tbody>
###xml 893 1328 893 1328 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value adjusted for center</th><th>Minor allele frequency</th></tr><tr><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr></thead><tbody><tr><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">36.2%</td><td char="." align="char">48.3%</td><td char="." align="char">15.5%</td><td/><td char="." align="char">0.40</td></tr><tr><td>Controls</td><td char="." align="char">41.8%</td><td char="." align="char">46.6%</td><td char="." align="char">11.6%</td><td char="." align="char">0.31</td><td char="." align="char">0.35</td></tr><tr><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">61.0%</td><td char="." align="char">34.2%</td><td char="." align="char">4.8%</td><td/><td char="." align="char">0.22</td></tr><tr><td>Controls</td><td char="." align="char">57.6%</td><td char="." align="char">35.5%</td><td char="." align="char">6.9%</td><td char="." align="char">0.55</td><td char="." align="char">0.25</td></tr><tr><td rowspan="2">G-80/in1A<sup>a</sup></td><td>Cases</td><td char="." align="char">54.9%</td><td char="." align="char">38.5%</td><td char="." align="char">6.6%</td><td/><td char="." align="char">0.26</td></tr><tr><td>Controls</td><td char="." align="char">49.3%</td><td char="." align="char">41.5%</td><td char="." align="char">9.2%</td><td char="." align="char">0.40</td><td char="." align="char">0.30</td></tr><tr><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">97.0%</td><td char="." align="char">3.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">95.2%</td><td char="." align="char">4.8%</td><td char="." align="char">0.0%</td><td char="." align="char">0.30</td><td char="." align="char">0.02</td></tr><tr><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">87.5%</td><td char="." align="char">12.1%</td><td char="." align="char">0.4%</td><td/><td char="." align="char">0.06</td></tr><tr><td>Controls</td><td char="." align="char">89.3%</td><td char="." align="char">10.3%</td><td char="." align="char">0.4%</td><td char="." align="char">0.82</td><td char="." align="char">0.06</td></tr><tr><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">92.1%</td><td char="." align="char">7.9%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.04</td></tr><tr><td>Controls</td><td char="." align="char">92.3%</td><td char="." align="char">7.7%</td><td char="." align="char">0.0%</td><td char="." align="char">0.97</td><td char="." align="char">0.04</td></tr></tbody></table>
###xml 1328 1330 1328 1330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">11</italic>
###xml 1365 1367 1365 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">12</italic>
###xml 1383 1385 1383 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">22</italic>
###xml 1328 1418 1328 1418 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><italic>11</italic> homozygotes for the major allele, <italic>12</italic> heterozygotes, <italic>22</italic> homozygotes for the minor allele</p>
###xml 1418 1419 1418 1419 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1418 1515 1418 1515 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41"><sup>a</sup>Nearly complete concordance with T-123/in1C (85% of subjects concordant for the 2 polymorphisms)</p>
###xml 1328 1515 1328 1515 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><italic>11</italic> homozygotes for the major allele, <italic>12</italic> heterozygotes, <italic>22</italic> homozygotes for the minor allele</p><p textid="41"><sup>a</sup>Nearly complete concordance with T-123/in1C (85% of subjects concordant for the 2 polymorphisms)</p></table-wrap-foot>
###xml 732 1515 732 1515 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="39">Genotype and minor allele frequencies in myocardial infarction cases (<italic>n</italic>&#8201;=&#8201;312) and controls (<italic>n</italic>&#8201;=&#8201;317) of the SIPLAC study (Belfast and Glasgow pooled, UK)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value adjusted for center</th><th>Minor allele frequency</th></tr><tr><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr></thead><tbody><tr><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">36.2%</td><td char="." align="char">48.3%</td><td char="." align="char">15.5%</td><td/><td char="." align="char">0.40</td></tr><tr><td>Controls</td><td char="." align="char">41.8%</td><td char="." align="char">46.6%</td><td char="." align="char">11.6%</td><td char="." align="char">0.31</td><td char="." align="char">0.35</td></tr><tr><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">61.0%</td><td char="." align="char">34.2%</td><td char="." align="char">4.8%</td><td/><td char="." align="char">0.22</td></tr><tr><td>Controls</td><td char="." align="char">57.6%</td><td char="." align="char">35.5%</td><td char="." align="char">6.9%</td><td char="." align="char">0.55</td><td char="." align="char">0.25</td></tr><tr><td rowspan="2">G-80/in1A<sup>a</sup></td><td>Cases</td><td char="." align="char">54.9%</td><td char="." align="char">38.5%</td><td char="." align="char">6.6%</td><td/><td char="." align="char">0.26</td></tr><tr><td>Controls</td><td char="." align="char">49.3%</td><td char="." align="char">41.5%</td><td char="." align="char">9.2%</td><td char="." align="char">0.40</td><td char="." align="char">0.30</td></tr><tr><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">97.0%</td><td char="." align="char">3.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">95.2%</td><td char="." align="char">4.8%</td><td char="." align="char">0.0%</td><td char="." align="char">0.30</td><td char="." align="char">0.02</td></tr><tr><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">87.5%</td><td char="." align="char">12.1%</td><td char="." align="char">0.4%</td><td/><td char="." align="char">0.06</td></tr><tr><td>Controls</td><td char="." align="char">89.3%</td><td char="." align="char">10.3%</td><td char="." align="char">0.4%</td><td char="." align="char">0.82</td><td char="." align="char">0.06</td></tr><tr><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">92.1%</td><td char="." align="char">7.9%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.04</td></tr><tr><td>Controls</td><td char="." align="char">92.3%</td><td char="." align="char">7.7%</td><td char="." align="char">0.0%</td><td char="." align="char">0.97</td><td char="." align="char">0.04</td></tr></tbody></table><table-wrap-foot><p textid="40"><italic>11</italic> homozygotes for the major allele, <italic>12</italic> heterozygotes, <italic>22</italic> homozygotes for the minor allele</p><p textid="41"><sup>a</sup>Nearly complete concordance with T-123/in1C (85% of subjects concordant for the 2 polymorphisms)</p></table-wrap-foot></table-wrap>
Seven polymorphisms were investigated in SIPLAC. C-85/in1T was not typed because of technical difficulties. The T+659C substitution, which had been found in a single chromosome among the 124 chromosomes screened, was not observed among the SIPLAC subjects. Accordingly, pairwise LD coefficients were estimated among the six remaining polymorphisms. All polymorphisms exhibited strong LD one with each other, and the six polymorphisms generated eight common haplotypes (frequency > 0.01). Genotype frequencies did not significantly differ between cases and controls for any polymorphism in the SIPLAC study (Table 3). The LD coefficients and haplotypic frequencies estimated in the SIPLAC study are accessible at (, genes: PLA2G10). Table 3Genotype and minor allele frequencies in myocardial infarction cases (n = 312) and controls (n = 317) of the SIPLAC study (Belfast and Glasgow pooled, UK)Genotype frequency (%)p value adjusted for centerMinor allele frequency111222T-512CCases36.2%48.3%15.5%0.40Controls41.8%46.6%11.6%0.310.35T-123/in1CCases61.0%34.2%4.8%0.22Controls57.6%35.5%6.9%0.550.25G-80/in1AaCases54.9%38.5%6.6%0.26Controls49.3%41.5%9.2%0.400.30R38CCases97.0%3.0%0.0%0.02Controls95.2%4.8%0.0%0.300.02C+264ACases87.5%12.1%0.4%0.06Controls89.3%10.3%0.4%0.820.06G+303CCases92.1%7.9%0.0%0.04Controls92.3%7.7%0.0%0.970.0411 homozygotes for the major allele, 12 heterozygotes, 22 homozygotes for the minor alleleaNearly complete concordance with T-123/in1C (85% of subjects concordant for the 2 polymorphisms)
###end p 38
###begin p 39
###xml 70 71 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 93 94 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Genotype and minor allele frequencies in myocardial infarction cases (n = 312) and controls (n = 317) of the SIPLAC study (Belfast and Glasgow pooled, UK)
###end p 39
###begin p 40
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">11</italic>
###xml 37 39 37 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">12</italic>
###xml 55 57 55 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">22</italic>
11 homozygotes for the major allele, 12 heterozygotes, 22 homozygotes for the minor allele
###end p 40
###begin p 41
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNearly complete concordance with T-123/in1C (85% of subjects concordant for the 2 polymorphisms)
###end p 41
###begin title 42
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
Association of the PLA2G10 polymorphisms with CAD risk in the AtheroGene study
###end title 42
###begin p 43
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab5" ref-type="table">5</xref>
###xml 525 532 525 532 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 604 605 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 629 630 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 651 655 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 532 678 532 678 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Genotype and minor allele frequencies in coronary artery disease cases (<italic>n</italic>&#8201;=&#8201;1,299) and controls (<italic>n</italic>&#8201;=&#8201;484) of the Athero<italic>Gene</italic> study (Mainz, Germany)</p>
###xml 532 678 532 678 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Genotype and minor allele frequencies in coronary artery disease cases (<italic>n</italic>&#8201;=&#8201;1,299) and controls (<italic>n</italic>&#8201;=&#8201;484) of the Athero<italic>Gene</italic> study (Mainz, Germany)</p></caption>
###xml 678 678 678 678 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2"/>
###xml 678 700 678 700 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">Genotype frequency (%)</th>
###xml 700 701 700 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 700 707 700 707 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 707 729 707 729 <th xmlns:xlink="http://www.w3.org/1999/xlink">Minor allele frequency</th>
###xml 678 729 678 729 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value</th><th>Minor allele frequency</th></tr>
###xml 729 729 729 729 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 729 729 729 729 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 729 731 729 731 <th xmlns:xlink="http://www.w3.org/1999/xlink">11</th>
###xml 731 733 731 733 <th xmlns:xlink="http://www.w3.org/1999/xlink">12</th>
###xml 733 735 733 735 <th xmlns:xlink="http://www.w3.org/1999/xlink">22</th>
###xml 735 735 735 735 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 735 735 735 735 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 729 735 729 735 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr>
###xml 678 735 678 735 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value</th><th>Minor allele frequency</th></tr><tr><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr></thead>
###xml 735 741 735 741 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">T-512C</td>
###xml 741 746 741 746 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 746 751 746 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">46.6%</td>
###xml 751 756 751 756 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">43.6%</td>
###xml 756 760 756 760 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.8%</td>
###xml 760 760 760 760 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 760 764 760 764 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.32</td>
###xml 735 764 735 764 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">46.6%</td><td char="." align="char">43.6%</td><td char="." align="char">9.8%</td><td/><td char="." align="char">0.32</td></tr>
###xml 764 772 764 772 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 772 777 772 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">46.0%</td>
###xml 777 782 777 782 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">43.4%</td>
###xml 782 787 782 787 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.6%</td>
###xml 787 791 787 791 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.88</td>
###xml 791 795 791 795 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.32</td>
###xml 764 795 764 795 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">46.0%</td><td char="." align="char">43.4%</td><td char="." align="char">10.6%</td><td char="." align="char">0.88</td><td char="." align="char">0.32</td></tr>
###xml 795 805 795 805 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">T-123/in1C</td>
###xml 805 810 805 810 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 810 815 810 815 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">60.4%</td>
###xml 815 820 815 820 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33.9%</td>
###xml 820 824 820 824 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.7%</td>
###xml 824 824 824 824 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 824 828 824 828 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.23</td>
###xml 795 828 795 828 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">60.4%</td><td char="." align="char">33.9%</td><td char="." align="char">5.7%</td><td/><td char="." align="char">0.23</td></tr>
###xml 828 836 828 836 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 836 841 836 841 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57.7%</td>
###xml 841 846 841 846 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36.9%</td>
###xml 846 850 846 850 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.4%</td>
###xml 850 854 850 854 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.50</td>
###xml 854 858 854 858 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.24</td>
###xml 828 858 828 858 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">57.7%</td><td char="." align="char">36.9%</td><td char="." align="char">5.4%</td><td char="." align="char">0.50</td><td char="." align="char">0.24</td></tr>
###xml 858 862 858 862 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">R38C</td>
###xml 862 867 862 867 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 867 872 867 872 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">96.4%</td>
###xml 872 876 872 876 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.5%</td>
###xml 876 880 876 880 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.1%</td>
###xml 880 880 880 880 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 880 884 880 884 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 858 884 858 884 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">96.4%</td><td char="." align="char">3.5%</td><td char="." align="char">0.1%</td><td/><td char="." align="char">0.02</td></tr>
###xml 884 892 884 892 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 892 897 892 897 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">95.4%</td>
###xml 897 901 897 901 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.6%</td>
###xml 901 905 901 905 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 905 909 905 909 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.50</td>
###xml 909 913 909 913 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 884 913 884 913 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">95.4%</td><td char="." align="char">4.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.50</td><td char="." align="char">0.02</td></tr>
###xml 913 919 913 919 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">C+264A</td>
###xml 919 924 919 924 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 924 929 924 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90.0%</td>
###xml 929 933 929 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.8%</td>
###xml 933 937 933 937 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.2%</td>
###xml 937 937 937 937 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 937 941 937 941 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.05</td>
###xml 913 941 913 941 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">90.0%</td><td char="." align="char">9.8%</td><td char="." align="char">0.2%</td><td/><td char="." align="char">0.05</td></tr>
###xml 941 949 941 949 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 949 954 949 954 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">90.4%</td>
###xml 954 958 954 958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.6%</td>
###xml 958 962 958 962 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 962 966 962 966 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.68</td>
###xml 966 970 966 970 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.05</td>
###xml 941 970 941 970 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">90.4%</td><td char="." align="char">9.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.68</td><td char="." align="char">0.05</td></tr>
###xml 970 976 970 976 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">G+303C</td>
###xml 976 981 976 981 <td xmlns:xlink="http://www.w3.org/1999/xlink">Cases</td>
###xml 981 986 981 986 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">96.0%</td>
###xml 986 990 986 990 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.0%</td>
###xml 990 994 990 994 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 994 994 994 994 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 994 998 994 998 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 970 998 970 998 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">96.0%</td><td char="." align="char">4.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr>
###xml 998 1006 998 1006 <td xmlns:xlink="http://www.w3.org/1999/xlink">Controls</td>
###xml 1006 1011 1006 1011 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">94.8%</td>
###xml 1011 1015 1011 1015 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.2%</td>
###xml 1015 1019 1015 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.0%</td>
###xml 1019 1023 1019 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.29</td>
###xml 1023 1027 1023 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.03</td>
###xml 998 1027 998 1027 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Controls</td><td char="." align="char">94.8%</td><td char="." align="char">5.2%</td><td char="." align="char">0.0%</td><td char="." align="char">0.29</td><td char="." align="char">0.03</td></tr>
###xml 735 1027 735 1027 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">46.6%</td><td char="." align="char">43.6%</td><td char="." align="char">9.8%</td><td/><td char="." align="char">0.32</td></tr><tr><td>Controls</td><td char="." align="char">46.0%</td><td char="." align="char">43.4%</td><td char="." align="char">10.6%</td><td char="." align="char">0.88</td><td char="." align="char">0.32</td></tr><tr><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">60.4%</td><td char="." align="char">33.9%</td><td char="." align="char">5.7%</td><td/><td char="." align="char">0.23</td></tr><tr><td>Controls</td><td char="." align="char">57.7%</td><td char="." align="char">36.9%</td><td char="." align="char">5.4%</td><td char="." align="char">0.50</td><td char="." align="char">0.24</td></tr><tr><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">96.4%</td><td char="." align="char">3.5%</td><td char="." align="char">0.1%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">95.4%</td><td char="." align="char">4.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.50</td><td char="." align="char">0.02</td></tr><tr><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">90.0%</td><td char="." align="char">9.8%</td><td char="." align="char">0.2%</td><td/><td char="." align="char">0.05</td></tr><tr><td>Controls</td><td char="." align="char">90.4%</td><td char="." align="char">9.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.68</td><td char="." align="char">0.05</td></tr><tr><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">96.0%</td><td char="." align="char">4.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">94.8%</td><td char="." align="char">5.2%</td><td char="." align="char">0.0%</td><td char="." align="char">0.29</td><td char="." align="char">0.03</td></tr></tbody>
###xml 678 1027 678 1027 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value</th><th>Minor allele frequency</th></tr><tr><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr></thead><tbody><tr><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">46.6%</td><td char="." align="char">43.6%</td><td char="." align="char">9.8%</td><td/><td char="." align="char">0.32</td></tr><tr><td>Controls</td><td char="." align="char">46.0%</td><td char="." align="char">43.4%</td><td char="." align="char">10.6%</td><td char="." align="char">0.88</td><td char="." align="char">0.32</td></tr><tr><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">60.4%</td><td char="." align="char">33.9%</td><td char="." align="char">5.7%</td><td/><td char="." align="char">0.23</td></tr><tr><td>Controls</td><td char="." align="char">57.7%</td><td char="." align="char">36.9%</td><td char="." align="char">5.4%</td><td char="." align="char">0.50</td><td char="." align="char">0.24</td></tr><tr><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">96.4%</td><td char="." align="char">3.5%</td><td char="." align="char">0.1%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">95.4%</td><td char="." align="char">4.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.50</td><td char="." align="char">0.02</td></tr><tr><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">90.0%</td><td char="." align="char">9.8%</td><td char="." align="char">0.2%</td><td/><td char="." align="char">0.05</td></tr><tr><td>Controls</td><td char="." align="char">90.4%</td><td char="." align="char">9.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.68</td><td char="." align="char">0.05</td></tr><tr><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">96.0%</td><td char="." align="char">4.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">94.8%</td><td char="." align="char">5.2%</td><td char="." align="char">0.0%</td><td char="." align="char">0.29</td><td char="." align="char">0.03</td></tr></tbody></table>
###xml 1027 1029 1027 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">11</italic>
###xml 1064 1066 1064 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">12</italic>
###xml 1082 1084 1082 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">22</italic>
###xml 1027 1117 1027 1117 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45"><italic>11</italic> homozygotes for the major allele, <italic>12</italic> heterozygotes, <italic>22</italic> homozygotes for the minor allele</p>
###xml 1027 1117 1027 1117 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45"><italic>11</italic> homozygotes for the major allele, <italic>12</italic> heterozygotes, <italic>22</italic> homozygotes for the minor allele</p></table-wrap-foot>
###xml 525 1117 525 1117 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="44">Genotype and minor allele frequencies in coronary artery disease cases (<italic>n</italic>&#8201;=&#8201;1,299) and controls (<italic>n</italic>&#8201;=&#8201;484) of the Athero<italic>Gene</italic> study (Mainz, Germany)</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"/><th colspan="3">Genotype frequency (%)</th><th><italic>p</italic> value</th><th>Minor allele frequency</th></tr><tr><th/><th/><th>11</th><th>12</th><th>22</th><th/><th/></tr></thead><tbody><tr><td rowspan="2">T-512C</td><td>Cases</td><td char="." align="char">46.6%</td><td char="." align="char">43.6%</td><td char="." align="char">9.8%</td><td/><td char="." align="char">0.32</td></tr><tr><td>Controls</td><td char="." align="char">46.0%</td><td char="." align="char">43.4%</td><td char="." align="char">10.6%</td><td char="." align="char">0.88</td><td char="." align="char">0.32</td></tr><tr><td rowspan="2">T-123/in1C</td><td>Cases</td><td char="." align="char">60.4%</td><td char="." align="char">33.9%</td><td char="." align="char">5.7%</td><td/><td char="." align="char">0.23</td></tr><tr><td>Controls</td><td char="." align="char">57.7%</td><td char="." align="char">36.9%</td><td char="." align="char">5.4%</td><td char="." align="char">0.50</td><td char="." align="char">0.24</td></tr><tr><td rowspan="2">R38C</td><td>Cases</td><td char="." align="char">96.4%</td><td char="." align="char">3.5%</td><td char="." align="char">0.1%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">95.4%</td><td char="." align="char">4.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.50</td><td char="." align="char">0.02</td></tr><tr><td rowspan="2">C+264A</td><td>Cases</td><td char="." align="char">90.0%</td><td char="." align="char">9.8%</td><td char="." align="char">0.2%</td><td/><td char="." align="char">0.05</td></tr><tr><td>Controls</td><td char="." align="char">90.4%</td><td char="." align="char">9.6%</td><td char="." align="char">0.0%</td><td char="." align="char">0.68</td><td char="." align="char">0.05</td></tr><tr><td rowspan="2">G+303C</td><td>Cases</td><td char="." align="char">96.0%</td><td char="." align="char">4.0%</td><td char="." align="char">0.0%</td><td/><td char="." align="char">0.02</td></tr><tr><td>Controls</td><td char="." align="char">94.8%</td><td char="." align="char">5.2%</td><td char="." align="char">0.0%</td><td char="." align="char">0.29</td><td char="." align="char">0.03</td></tr></tbody></table><table-wrap-foot><p textid="45"><italic>11</italic> homozygotes for the major allele, <italic>12</italic> heterozygotes, <italic>22</italic> homozygotes for the minor allele</p></table-wrap-foot></table-wrap>
###xml 1117 1124 1117 1124 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;5</label>
###xml 1221 1225 1221 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 1124 1231 1124 1231 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Main haplotypic frequencies estimated in coronary artery disease cases and controls of the Athero<italic>Gene</italic> study</p>
###xml 1124 1231 1124 1231 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Main haplotypic frequencies estimated in coronary artery disease cases and controls of the Athero<italic>Gene</italic> study</p></caption>
###xml 1231 1241 1231 1241 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="5">Haplotypes</th>
###xml 1241 1250 1241 1250 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="2">Frequency</th>
###xml 1231 1250 1231 1250 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th colspan="5">Haplotypes</th><th colspan="2">Frequency</th></tr>
###xml 1250 1256 1250 1256 <th xmlns:xlink="http://www.w3.org/1999/xlink">T-512C</th>
###xml 1256 1266 1256 1266 <th xmlns:xlink="http://www.w3.org/1999/xlink">T-123/in1C</th>
###xml 1266 1270 1266 1270 <th xmlns:xlink="http://www.w3.org/1999/xlink">R38C</th>
###xml 1270 1276 1270 1276 <th xmlns:xlink="http://www.w3.org/1999/xlink">C+264A</th>
###xml 1276 1282 1276 1282 <th xmlns:xlink="http://www.w3.org/1999/xlink">G+303C</th>
###xml 1282 1303 1282 1303 <th xmlns:xlink="http://www.w3.org/1999/xlink">Cases (2,426 alleles)</th>
###xml 1303 1325 1303 1325 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls (940 alleles)</th>
###xml 1250 1325 1250 1325 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>T-512C</th><th>T-123/in1C</th><th>R38C</th><th>C+264A</th><th>G+303C</th><th>Cases (2,426 alleles)</th><th>Controls (940 alleles)</th></tr>
###xml 1231 1325 1231 1325 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th colspan="5">Haplotypes</th><th colspan="2">Frequency</th></tr><tr><th>T-512C</th><th>T-123/in1C</th><th>R38C</th><th>C+264A</th><th>G+303C</th><th>Cases (2,426 alleles)</th><th>Controls (940 alleles)</th></tr></thead>
###xml 1325 1326 1325 1326 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1326 1327 1326 1327 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1327 1328 1327 1328 <td xmlns:xlink="http://www.w3.org/1999/xlink">R</td>
###xml 1328 1329 1328 1329 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1329 1330 1329 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink">G</td>
###xml 1330 1335 1330 1335 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.399</td>
###xml 1335 1340 1335 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.390</td>
###xml 1325 1340 1325 1340 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.399</td><td char="." align="char">0.390</td></tr>
###xml 1340 1341 1340 1341 <td xmlns:xlink="http://www.w3.org/1999/xlink">c</td>
###xml 1341 1342 1341 1342 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1342 1343 1342 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink">R</td>
###xml 1343 1344 1343 1344 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1344 1345 1344 1345 <td xmlns:xlink="http://www.w3.org/1999/xlink">G</td>
###xml 1345 1350 1345 1350 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.297</td>
###xml 1350 1355 1350 1355 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.293</td>
###xml 1340 1355 1340 1355 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>c</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.297</td><td char="." align="char">0.293</td></tr>
###xml 1355 1356 1355 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1356 1357 1356 1357 <td xmlns:xlink="http://www.w3.org/1999/xlink">c</td>
###xml 1357 1358 1357 1358 <td xmlns:xlink="http://www.w3.org/1999/xlink">R</td>
###xml 1358 1359 1358 1359 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1359 1360 1359 1360 <td xmlns:xlink="http://www.w3.org/1999/xlink">G</td>
###xml 1360 1365 1360 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.208</td>
###xml 1365 1370 1365 1370 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.217</td>
###xml 1355 1370 1355 1370 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T</td><td>c</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.208</td><td char="." align="char">0.217</td></tr>
###xml 1370 1371 1370 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1371 1372 1371 1372 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1372 1373 1372 1373 <td xmlns:xlink="http://www.w3.org/1999/xlink">R</td>
###xml 1373 1374 1373 1374 <td xmlns:xlink="http://www.w3.org/1999/xlink">a</td>
###xml 1374 1375 1374 1375 <td xmlns:xlink="http://www.w3.org/1999/xlink">G</td>
###xml 1375 1380 1375 1380 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.054</td>
###xml 1380 1385 1380 1385 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.048</td>
###xml 1370 1385 1370 1385 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T</td><td>T</td><td>R</td><td>a</td><td>G</td><td char="." align="char">0.054</td><td char="." align="char">0.048</td></tr>
###xml 1385 1386 1385 1386 <td xmlns:xlink="http://www.w3.org/1999/xlink">c</td>
###xml 1386 1387 1386 1387 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1387 1388 1387 1388 <td xmlns:xlink="http://www.w3.org/1999/xlink">R</td>
###xml 1388 1389 1388 1389 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1389 1390 1389 1390 <td xmlns:xlink="http://www.w3.org/1999/xlink">c</td>
###xml 1390 1395 1390 1395 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.018</td>
###xml 1395 1400 1395 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.026</td>
###xml 1385 1400 1385 1400 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>c</td><td>T</td><td>R</td><td>C</td><td>c</td><td char="." align="char">0.018</td><td char="." align="char">0.026</td></tr>
###xml 1400 1401 1400 1401 <td xmlns:xlink="http://www.w3.org/1999/xlink">T</td>
###xml 1401 1402 1401 1402 <td xmlns:xlink="http://www.w3.org/1999/xlink">c</td>
###xml 1402 1403 1402 1403 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1403 1404 1403 1404 <td xmlns:xlink="http://www.w3.org/1999/xlink">C</td>
###xml 1404 1405 1404 1405 <td xmlns:xlink="http://www.w3.org/1999/xlink">G</td>
###xml 1405 1410 1405 1410 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.014</td>
###xml 1410 1415 1410 1415 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.017</td>
###xml 1400 1415 1400 1415 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>T</td><td>c</td><td>C</td><td>C</td><td>G</td><td char="." align="char">0.014</td><td char="." align="char">0.017</td></tr>
###xml 1325 1415 1325 1415 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>T</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.399</td><td char="." align="char">0.390</td></tr><tr><td>c</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.297</td><td char="." align="char">0.293</td></tr><tr><td>T</td><td>c</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.208</td><td char="." align="char">0.217</td></tr><tr><td>T</td><td>T</td><td>R</td><td>a</td><td>G</td><td char="." align="char">0.054</td><td char="." align="char">0.048</td></tr><tr><td>c</td><td>T</td><td>R</td><td>C</td><td>c</td><td char="." align="char">0.018</td><td char="." align="char">0.026</td></tr><tr><td>T</td><td>c</td><td>C</td><td>C</td><td>G</td><td char="." align="char">0.014</td><td char="." align="char">0.017</td></tr></tbody>
###xml 1231 1415 1231 1415 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th colspan="5">Haplotypes</th><th colspan="2">Frequency</th></tr><tr><th>T-512C</th><th>T-123/in1C</th><th>R38C</th><th>C+264A</th><th>G+303C</th><th>Cases (2,426 alleles)</th><th>Controls (940 alleles)</th></tr></thead><tbody><tr><td>T</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.399</td><td char="." align="char">0.390</td></tr><tr><td>c</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.297</td><td char="." align="char">0.293</td></tr><tr><td>T</td><td>c</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.208</td><td char="." align="char">0.217</td></tr><tr><td>T</td><td>T</td><td>R</td><td>a</td><td>G</td><td char="." align="char">0.054</td><td char="." align="char">0.048</td></tr><tr><td>c</td><td>T</td><td>R</td><td>C</td><td>c</td><td char="." align="char">0.018</td><td char="." align="char">0.026</td></tr><tr><td>T</td><td>c</td><td>C</td><td>C</td><td>G</td><td char="." align="char">0.014</td><td char="." align="char">0.017</td></tr></tbody></table>
###xml 1461 1462 1461 1462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1415 1469 1415 1469 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Global difference between cases and controls: <italic>p</italic>&#8201;=&#8201;0.72</p>
###xml 1415 1469 1415 1469 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Global difference between cases and controls: <italic>p</italic>&#8201;=&#8201;0.72</p></table-wrap-foot>
###xml 1117 1469 1117 1469 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table&#160;5</label><caption><p textid="46">Main haplotypic frequencies estimated in coronary artery disease cases and controls of the Athero<italic>Gene</italic> study</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Haplotypes</th><th colspan="2">Frequency</th></tr><tr><th>T-512C</th><th>T-123/in1C</th><th>R38C</th><th>C+264A</th><th>G+303C</th><th>Cases (2,426 alleles)</th><th>Controls (940 alleles)</th></tr></thead><tbody><tr><td>T</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.399</td><td char="." align="char">0.390</td></tr><tr><td>c</td><td>T</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.297</td><td char="." align="char">0.293</td></tr><tr><td>T</td><td>c</td><td>R</td><td>C</td><td>G</td><td char="." align="char">0.208</td><td char="." align="char">0.217</td></tr><tr><td>T</td><td>T</td><td>R</td><td>a</td><td>G</td><td char="." align="char">0.054</td><td char="." align="char">0.048</td></tr><tr><td>c</td><td>T</td><td>R</td><td>C</td><td>c</td><td char="." align="char">0.018</td><td char="." align="char">0.026</td></tr><tr><td>T</td><td>c</td><td>C</td><td>C</td><td>G</td><td char="." align="char">0.014</td><td char="." align="char">0.017</td></tr></tbody></table><table-wrap-foot><p textid="47">Global difference between cases and controls: <italic>p</italic>&#8201;=&#8201;0.72</p></table-wrap-foot></table-wrap>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
The AtheroGene study was genotyped for five polymorphisms: T-512C, T-123/in1C, R38C, C+264A, and G+303C. There was no significant departure from Hardy-Weinberg equilibrium in controls. In single-locus analysis, none of the polymorphisms was significantly associated with CAD risk (Table 4). Haplotype frequencies did not differ between cases and controls (Table 5). Further subdivision of CAD cases into patients with stable angina pectoris and those with an acute coronary syndrome did not provide significant associations. Table 4Genotype and minor allele frequencies in coronary artery disease cases (n = 1,299) and controls (n = 484) of the AtheroGene study (Mainz, Germany)Genotype frequency (%)p valueMinor allele frequency111222T-512CCases46.6%43.6%9.8%0.32Controls46.0%43.4%10.6%0.880.32T-123/in1CCases60.4%33.9%5.7%0.23Controls57.7%36.9%5.4%0.500.24R38CCases96.4%3.5%0.1%0.02Controls95.4%4.6%0.0%0.500.02C+264ACases90.0%9.8%0.2%0.05Controls90.4%9.6%0.0%0.680.05G+303CCases96.0%4.0%0.0%0.02Controls94.8%5.2%0.0%0.290.0311 homozygotes for the major allele, 12 heterozygotes, 22 homozygotes for the minor alleleTable 5Main haplotypic frequencies estimated in coronary artery disease cases and controls of the AtheroGene studyHaplotypesFrequencyT-512CT-123/in1CR38CC+264AG+303CCases (2,426 alleles)Controls (940 alleles)TTRCG0.3990.390cTRCG0.2970.293TcRCG0.2080.217TTRaG0.0540.048cTRCc0.0180.026TcCCG0.0140.017Global difference between cases and controls: p = 0.72
###end p 43
###begin p 44
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
Genotype and minor allele frequencies in coronary artery disease cases (n = 1,299) and controls (n = 484) of the AtheroGene study (Mainz, Germany)
###end p 44
###begin p 45
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">11</italic>
###xml 37 39 37 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">12</italic>
###xml 55 57 55 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">22</italic>
11 homozygotes for the major allele, 12 heterozygotes, 22 homozygotes for the minor allele
###end p 45
###begin p 46
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
Main haplotypic frequencies estimated in coronary artery disease cases and controls of the AtheroGene study
###end p 46
###begin p 47
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Global difference between cases and controls: p = 0.72
###end p 47
###begin title 48
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
Association of polymorphisms with cardiovascular risk factors and prospective cardiovascular outcome in the AtheroGene study
###end title 48
###begin p 49
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab6" ref-type="table">6</xref>
###xml 383 390 383 390 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;6</label>
###xml 390 473 390 473 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">Hazard ratio for cardiovascular event at follow-up associated with the -512C allele</p>
###xml 390 473 390 473 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50">Hazard ratio for cardiovascular event at follow-up associated with the -512C allele</p></caption>
###xml 473 493 473 493 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2" colspan="2">Cardiovascular event</th>
###xml 493 508 493 508 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3">T-512C genotype</th>
###xml 473 508 473 508 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2" colspan="2">Cardiovascular event</th><th colspan="3">T-512C genotype</th></tr>
###xml 508 510 508 510 <th xmlns:xlink="http://www.w3.org/1999/xlink">TT</th>
###xml 510 512 510 512 <th xmlns:xlink="http://www.w3.org/1999/xlink">TC</th>
###xml 512 514 512 514 <th xmlns:xlink="http://www.w3.org/1999/xlink">CC</th>
###xml 508 514 508 514 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>TT</th><th>TC</th><th>CC</th></tr>
###xml 473 514 473 514 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2" colspan="2">Cardiovascular event</th><th colspan="3">T-512C genotype</th></tr><tr><th>TT</th><th>TC</th><th>CC</th></tr></thead>
###xml 514 516 514 516 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">No</td>
###xml 516 522 516 522 <td xmlns:xlink="http://www.w3.org/1999/xlink">Number</td>
###xml 522 525 522 525 <td xmlns:xlink="http://www.w3.org/1999/xlink">469</td>
###xml 525 528 525 528 <td xmlns:xlink="http://www.w3.org/1999/xlink">461</td>
###xml 528 531 528 531 <td xmlns:xlink="http://www.w3.org/1999/xlink">109</td>
###xml 514 531 514 531 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">No</td><td>Number</td><td>469</td><td>461</td><td>109</td></tr>
###xml 531 538 531 538 <td xmlns:xlink="http://www.w3.org/1999/xlink">Percent</td>
###xml 538 543 538 543 <td xmlns:xlink="http://www.w3.org/1999/xlink">45.1%</td>
###xml 543 548 543 548 <td xmlns:xlink="http://www.w3.org/1999/xlink">44.4%</td>
###xml 548 553 548 553 <td xmlns:xlink="http://www.w3.org/1999/xlink">10.5%</td>
###xml 531 553 531 553 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Percent</td><td>45.1%</td><td>44.4%</td><td>10.5%</td></tr>
###xml 553 556 553 556 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Yes</td>
###xml 556 562 556 562 <td xmlns:xlink="http://www.w3.org/1999/xlink">Number</td>
###xml 562 565 562 565 <td xmlns:xlink="http://www.w3.org/1999/xlink">125</td>
###xml 565 567 565 567 <td xmlns:xlink="http://www.w3.org/1999/xlink">94</td>
###xml 567 569 567 569 <td xmlns:xlink="http://www.w3.org/1999/xlink">16</td>
###xml 553 569 553 569 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td rowspan="2">Yes</td><td>Number</td><td>125</td><td>94</td><td>16</td></tr>
###xml 569 576 569 576 <td xmlns:xlink="http://www.w3.org/1999/xlink">Percent</td>
###xml 576 581 576 581 <td xmlns:xlink="http://www.w3.org/1999/xlink">53.2%</td>
###xml 581 586 581 586 <td xmlns:xlink="http://www.w3.org/1999/xlink">40.0%</td>
###xml 586 590 586 590 <td xmlns:xlink="http://www.w3.org/1999/xlink">6.8%</td>
###xml 569 590 569 590 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Percent</td><td>53.2%</td><td>40.0%</td><td>6.8%</td></tr>
###xml 590 611 590 611 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hazard ratio (95% CI)</td>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 611 636 611 636 <td xmlns:xlink="http://www.w3.org/1999/xlink" colspan="4">0.76 [0.62&#8211;0.94] <italic>p</italic>&#8201;&lt;&#8201;0.01</td>
###xml 590 636 590 636 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hazard ratio (95% CI)</td><td colspan="4">0.76 [0.62&#8211;0.94] <italic>p</italic>&#8201;&lt;&#8201;0.01</td></tr>
###xml 514 636 514 636 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td rowspan="2">No</td><td>Number</td><td>469</td><td>461</td><td>109</td></tr><tr><td>Percent</td><td>45.1%</td><td>44.4%</td><td>10.5%</td></tr><tr><td rowspan="2">Yes</td><td>Number</td><td>125</td><td>94</td><td>16</td></tr><tr><td>Percent</td><td>53.2%</td><td>40.0%</td><td>6.8%</td></tr><tr><td>Hazard ratio (95% CI)</td><td colspan="4">0.76 [0.62&#8211;0.94] <italic>p</italic>&#8201;&lt;&#8201;0.01</td></tr></tbody>
###xml 473 636 473 636 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">Cardiovascular event</th><th colspan="3">T-512C genotype</th></tr><tr><th>TT</th><th>TC</th><th>CC</th></tr></thead><tbody><tr><td rowspan="2">No</td><td>Number</td><td>469</td><td>461</td><td>109</td></tr><tr><td>Percent</td><td>45.1%</td><td>44.4%</td><td>10.5%</td></tr><tr><td rowspan="2">Yes</td><td>Number</td><td>125</td><td>94</td><td>16</td></tr><tr><td>Percent</td><td>53.2%</td><td>40.0%</td><td>6.8%</td></tr><tr><td>Hazard ratio (95% CI)</td><td colspan="4">0.76 [0.62&#8211;0.94] <italic>p</italic>&#8201;&lt;&#8201;0.01</td></tr></tbody></table>
###xml 636 713 636 713 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Cardiovascular event: cardiovascular death or non-fatal myocardial infarction</p>
###xml 713 748 713 748 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Median time at follow-up: 6.2&#160;years</p>
###xml 748 849 748 849 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="53">Hazard ratio for one copy of the C allele, assuming an additive allele effect adjusted on age and sex</p>
###xml 636 849 636 849 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Cardiovascular event: cardiovascular death or non-fatal myocardial infarction</p><p textid="52">Median time at follow-up: 6.2&#160;years</p><p textid="53">Hazard ratio for one copy of the C allele, assuming an additive allele effect adjusted on age and sex</p></table-wrap-foot>
###xml 383 849 383 849 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab6"><label>Table&#160;6</label><caption><p textid="50">Hazard ratio for cardiovascular event at follow-up associated with the -512C allele</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">Cardiovascular event</th><th colspan="3">T-512C genotype</th></tr><tr><th>TT</th><th>TC</th><th>CC</th></tr></thead><tbody><tr><td rowspan="2">No</td><td>Number</td><td>469</td><td>461</td><td>109</td></tr><tr><td>Percent</td><td>45.1%</td><td>44.4%</td><td>10.5%</td></tr><tr><td rowspan="2">Yes</td><td>Number</td><td>125</td><td>94</td><td>16</td></tr><tr><td>Percent</td><td>53.2%</td><td>40.0%</td><td>6.8%</td></tr><tr><td>Hazard ratio (95% CI)</td><td colspan="4">0.76 [0.62&#8211;0.94] <italic>p</italic>&#8201;&lt;&#8201;0.01</td></tr></tbody></table><table-wrap-foot><p textid="51">Cardiovascular event: cardiovascular death or non-fatal myocardial infarction</p><p textid="52">Median time at follow-up: 6.2&#160;years</p><p textid="53">Hazard ratio for one copy of the C allele, assuming an additive allele effect adjusted on age and sex</p></table-wrap-foot></table-wrap>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
No significant association was found with baseline lipids or inflammatory markers (data not shown). In CAD patients, the minor allele of T-512C was associated with a decreased risk of death from cardiovascular causes and non-fatal MI during the follow-up (hazard ratio [95% CI] for one copy of the C allele assuming an additive allele effect: 0.76 [0.62-0.94] p < 0.01) and Table 6. Table 6Hazard ratio for cardiovascular event at follow-up associated with the -512C alleleCardiovascular eventT-512C genotypeTTTCCCNoNumber469461109Percent45.1%44.4%10.5%YesNumber1259416Percent53.2%40.0%6.8%Hazard ratio (95% CI)0.76 [0.62-0.94] p < 0.01Cardiovascular event: cardiovascular death or non-fatal myocardial infarctionMedian time at follow-up: 6.2 yearsHazard ratio for one copy of the C allele, assuming an additive allele effect adjusted on age and sex
###end p 49
###begin p 50
Hazard ratio for cardiovascular event at follow-up associated with the -512C allele
###end p 50
###begin p 51
Cardiovascular event: cardiovascular death or non-fatal myocardial infarction
###end p 51
###begin p 52
Median time at follow-up: 6.2 years
###end p 52
###begin p 53
Hazard ratio for one copy of the C allele, assuming an additive allele effect adjusted on age and sex
###end p 53
###begin title 54
Functional study of the R38C polymorphism
###end title 54
###begin p 55
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1162 1163 1162 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1170 1176 1170 1176 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1176 1177 1176 1177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1362 1366 1362 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 1372 1377 1372 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1483 1486 1483 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1488 1489 1488 1489 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1652 1655 1652 1655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1679 1683 1679 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 1783 1806 1783 1806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 1176 1825 1176 1825 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="56"><bold>a</bold> Schematic representation of the hGX sPLA2 protein containing the R38C polymorphism in the propeptide region. The arginine doublet preceding the mature protein sequence is indicated in <italic>bold</italic>. The <italic>arrow</italic> indicates the allelic substitution, and the amino acid change (arginine R to cysteine C) is indicated in <italic>red</italic>. <bold>b</bold> Immunofluorescence localization of hGX sPLA2 in COS-7 cells transfected with vectors encoding the R38 and the C38 proteins. The hGX sPLA2 protein is labeled with <italic>red</italic>. Nucleus is labeled in <italic>blue</italic> with DAPI. Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Magnification: 50</p>
###xml 1176 1825 1176 1825 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="56"><bold>a</bold> Schematic representation of the hGX sPLA2 protein containing the R38C polymorphism in the propeptide region. The arginine doublet preceding the mature protein sequence is indicated in <italic>bold</italic>. The <italic>arrow</italic> indicates the allelic substitution, and the amino acid change (arginine R to cysteine C) is indicated in <italic>red</italic>. <bold>b</bold> Immunofluorescence localization of hGX sPLA2 in COS-7 cells transfected with vectors encoding the R38 and the C38 proteins. The hGX sPLA2 protein is labeled with <italic>red</italic>. Nucleus is labeled in <italic>blue</italic> with DAPI. Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Magnification: 50</p></caption>
###xml 1825 1825 1825 1825 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2009_483_Fig2_HTML" id="MO2"/>
###xml 1170 1825 1170 1825 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="56"><bold>a</bold> Schematic representation of the hGX sPLA2 protein containing the R38C polymorphism in the propeptide region. The arginine doublet preceding the mature protein sequence is indicated in <italic>bold</italic>. The <italic>arrow</italic> indicates the allelic substitution, and the amino acid change (arginine R to cysteine C) is indicated in <italic>red</italic>. <bold>b</bold> Immunofluorescence localization of hGX sPLA2 in COS-7 cells transfected with vectors encoding the R38 and the C38 proteins. The hGX sPLA2 protein is labeled with <italic>red</italic>. Nucleus is labeled in <italic>blue</italic> with DAPI. Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Magnification: 50</p></caption><graphic position="anchor" xlink:href="109_2009_483_Fig2_HTML" id="MO2"/></fig>
###xml 1825 1831 1825 1831 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1957 1958 1957 1958 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1968 1969 1968 1969 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2089 2092 2089 2092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 2151 2156 2151 2156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 2230 2235 2230 2235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 2364 2387 2364 2387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 1831 2430 1831 2430 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="57">Subcellular immunofluorescence localization of hGX sPLA2 in COS-7 cells transiently transfected with vectors encoding either (<bold>a</bold>) R38 or (<bold>b</bold>) C38 hGX sPLA2. Twenty hours after transfection cells were fixed and stained with rabbit polyclonal against hGX sPLA2 (<italic>red</italic>) and either a mouse monoclonal against the ER marker PDI (<italic>green</italic>), or a mouse monoclonal against the Golgi apparatus marker 58&#160;K protein (<italic>green</italic>). Nucleus is labelled in blue with DAPI Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Magnification 50 for ER and 100 for Golgi</p>
###xml 1831 2430 1831 2430 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="57">Subcellular immunofluorescence localization of hGX sPLA2 in COS-7 cells transiently transfected with vectors encoding either (<bold>a</bold>) R38 or (<bold>b</bold>) C38 hGX sPLA2. Twenty hours after transfection cells were fixed and stained with rabbit polyclonal against hGX sPLA2 (<italic>red</italic>) and either a mouse monoclonal against the ER marker PDI (<italic>green</italic>), or a mouse monoclonal against the Golgi apparatus marker 58&#160;K protein (<italic>green</italic>). Nucleus is labelled in blue with DAPI Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Magnification 50 for ER and 100 for Golgi</p></caption>
###xml 2430 2430 2430 2430 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2009_483_Fig3_HTML" id="MO3"/>
###xml 1825 2430 1825 2430 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="57">Subcellular immunofluorescence localization of hGX sPLA2 in COS-7 cells transiently transfected with vectors encoding either (<bold>a</bold>) R38 or (<bold>b</bold>) C38 hGX sPLA2. Twenty hours after transfection cells were fixed and stained with rabbit polyclonal against hGX sPLA2 (<italic>red</italic>) and either a mouse monoclonal against the ER marker PDI (<italic>green</italic>), or a mouse monoclonal against the Golgi apparatus marker 58&#160;K protein (<italic>green</italic>). Nucleus is labelled in blue with DAPI Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Magnification 50 for ER and 100 for Golgi</p></caption><graphic position="anchor" xlink:href="109_2009_483_Fig3_HTML" id="MO3"/></fig>
###xml 2052 2058 <span type="species:ncbi:9986">rabbit</span>
###xml 2107 2112 <span type="species:ncbi:10090">mouse</span>
###xml 2164 2169 <span type="species:ncbi:10090">mouse</span>
Because of the potential role of hGX sPLA2 in inflammatory processes, we investigated whether the non-synonymous R38C polymorphism might have a functional impact on the protein. The R38C polymorphism, by substituting an arginine to a cysteine at codon 38 (Fig. 2a), leads to an odd number of cysteines in the hGX sPLA2 protein, which may result in misfolding and/or mistargeting and subsequent protein degradation. To analyze the effect of the mutation, we prepared plasmid constructs for HA-tagged hGX sPLA2 with R38 or C38 in the propeptide segment by site-directed mutagenesis and analyzed their expression after transient transfection into COS-7 cells. Fluorescence immunocytochemistry performed 24 h after transfection showed that both R38 and C38 proteins are present intracellularly (Fig. 2b). To determine the subcellular location of the C38 protein, cells were fixed and immunostained with antibodies to PDI and 58 K Golgi proteins, which are well established markers of the ER and the Golgi apparatus, respectively. No difference was observed in their subcellular localization as both R38 and C38 proteins colocalized with ER and Golgi apparatus (Fig. 3a, b). Fig. 2a Schematic representation of the hGX sPLA2 protein containing the R38C polymorphism in the propeptide region. The arginine doublet preceding the mature protein sequence is indicated in bold. The arrow indicates the allelic substitution, and the amino acid change (arginine R to cysteine C) is indicated in red. b Immunofluorescence localization of hGX sPLA2 in COS-7 cells transfected with vectors encoding the R38 and the C38 proteins. The hGX sPLA2 protein is labeled with red. Nucleus is labeled in blue with DAPI. Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in "Materials and methods". Magnification: 50Fig. 3Subcellular immunofluorescence localization of hGX sPLA2 in COS-7 cells transiently transfected with vectors encoding either (a) R38 or (b) C38 hGX sPLA2. Twenty hours after transfection cells were fixed and stained with rabbit polyclonal against hGX sPLA2 (red) and either a mouse monoclonal against the ER marker PDI (green), or a mouse monoclonal against the Golgi apparatus marker 58 K protein (green). Nucleus is labelled in blue with DAPI Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in "Materials and methods". Magnification 50 for ER and 100 for Golgi
###end p 55
###begin p 56
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bold</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 307 310 307 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 312 313 312 313 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 476 479 476 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 607 630 607 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
a Schematic representation of the hGX sPLA2 protein containing the R38C polymorphism in the propeptide region. The arginine doublet preceding the mature protein sequence is indicated in bold. The arrow indicates the allelic substitution, and the amino acid change (arginine R to cysteine C) is indicated in red. b Immunofluorescence localization of hGX sPLA2 in COS-7 cells transfected with vectors encoding the R38 and the C38 proteins. The hGX sPLA2 protein is labeled with red. Nucleus is labeled in blue with DAPI. Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in "Materials and methods". Magnification: 50
###end p 56
###begin p 57
###xml 126 127 126 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 137 138 137 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 258 261 258 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 320 325 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 399 404 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 533 556 533 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 221 227 <span type="species:ncbi:9986">rabbit</span>
###xml 276 281 <span type="species:ncbi:10090">mouse</span>
###xml 333 338 <span type="species:ncbi:10090">mouse</span>
Subcellular immunofluorescence localization of hGX sPLA2 in COS-7 cells transiently transfected with vectors encoding either (a) R38 or (b) C38 hGX sPLA2. Twenty hours after transfection cells were fixed and stained with rabbit polyclonal against hGX sPLA2 (red) and either a mouse monoclonal against the ER marker PDI (green), or a mouse monoclonal against the Golgi apparatus marker 58 K protein (green). Nucleus is labelled in blue with DAPI Confocal analysis was performed on a Leica SP2-AOBS confocal microscope as described in "Materials and methods". Magnification 50 for ER and 100 for Golgi
###end p 57
###begin p 58
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 1055 1061 1055 1061 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1061 1062 1061 1062 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1119 1135 1119 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 1298 1321 1298 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 1412 1413 1412 1413 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1631 1654 1631 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 1061 1743 1061 1743 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="59"><bold>a</bold> hGX sPLA2 enzymatic activity measured with radiolabeled <italic>Escherichia coli</italic> membranes in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. A representative experiment of at least three experiments with similar results is shown. <bold>b</bold> Concentration of hGX sPLA2 protein quantified in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins using TR-FIA assay as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. A representative experiment of at least three experiments with similar results is shown</p>
###xml 1061 1743 1061 1743 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="59"><bold>a</bold> hGX sPLA2 enzymatic activity measured with radiolabeled <italic>Escherichia coli</italic> membranes in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. A representative experiment of at least three experiments with similar results is shown. <bold>b</bold> Concentration of hGX sPLA2 protein quantified in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins using TR-FIA assay as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. A representative experiment of at least three experiments with similar results is shown</p></caption>
###xml 1743 1743 1743 1743 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2009_483_Fig4_HTML" id="MO4"/>
###xml 1055 1743 1055 1743 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="59"><bold>a</bold> hGX sPLA2 enzymatic activity measured with radiolabeled <italic>Escherichia coli</italic> membranes in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. A representative experiment of at least three experiments with similar results is shown. <bold>b</bold> Concentration of hGX sPLA2 protein quantified in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins using TR-FIA assay as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. A representative experiment of at least three experiments with similar results is shown</p></caption><graphic position="anchor" xlink:href="109_2009_483_Fig4_HTML" id="MO4"/></fig>
###xml 145 152 <span type="species:ncbi:562">E. coli</span>
###xml 1119 1135 <span type="species:ncbi:562">Escherichia coli</span>
We next determined the level of expression of hGX sPLA2 in cell lysates and cell supernatants by measuring catalytic activity with the sensitive E. coli assay [25] and total protein amount by TR-FIA [23]. In both cell lysate and supernatant, the level of sPLA2 catalytic activity measured for the C38 protein was dramatically lower than that measured for the R38 protein (Fig. 4a). TR-FIA analyses confirmed the lower expression of the C38 sPLA2 protein as compared to R38 (Fig. 4b). Together, our results indicate that the R38C polymorphism has a profound impact on protein activity and expression. In order to test whether the mutation has an impact on the expression of hGX sPLA2 at the messenger RNA (mRNA) level, we performed real-time quantitative PCR (RT-QPCR) analysis of COS-7 transfected cells with either the mutant or the wild type protein. The expression of hGX sPLA2 mRNA in cells transfected with the two expression plasmids was similar (data not shown), suggesting that the polymorphism has no effect on the mRNA production and stability. Fig. 4a hGX sPLA2 enzymatic activity measured with radiolabeled Escherichia coli membranes in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins as described in "Materials and methods". A representative experiment of at least three experiments with similar results is shown. b Concentration of hGX sPLA2 protein quantified in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins using TR-FIA assay as described in "Materials and methods". A representative experiment of at least three experiments with similar results is shown
###end p 58
###begin p 59
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 58 74 58 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 237 260 237 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 351 352 351 352 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 570 593 570 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 58 74 <span type="species:ncbi:562">Escherichia coli</span>
a hGX sPLA2 enzymatic activity measured with radiolabeled Escherichia coli membranes in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins as described in "Materials and methods". A representative experiment of at least three experiments with similar results is shown. b Concentration of hGX sPLA2 protein quantified in supernatant and cell lysates of COS-7 cells transfected either with an empty vector or with vectors encoding the R38 or C38 proteins using TR-FIA assay as described in "Materials and methods". A representative experiment of at least three experiments with similar results is shown
###end p 59
###begin p 60
###xml 130 132 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 590 591 560 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 668 669 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 811 812 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1067 1073 1031 1037 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 1344 1345 1296 1297 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1364 1365 1316 1317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1406 1429 1358 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 1431 1432 1383 1384 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1646 1669 1586 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 1073 1780 1037 1720 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="61">Effect of temperature cell growth on the expression of hGX sPLA2. COS-7 cells transfected with either R38- or C38-containing expression vectors were grown at 30&#176;C or 37&#176;C for 72&#160;h. The total amount of hGX sPLA2 protein was then quantified in the cell lysate (<bold>a</bold>) and supernatant (<bold>b</bold>) using the TR-FIA assay as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. <bold>c</bold> COS-7 cells transfected with either the R38- or C38-containing or empty expression vectors were grown at 30&#176;C or 37&#176;C for 72&#160;h, and hGX sPLA2 activity was measured in cell supernatants as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Cells transfected with the empty vector showed no detectable hGX sPLA2 protein or enzyme activity (not shown)</p>
###xml 1073 1780 1037 1720 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="61">Effect of temperature cell growth on the expression of hGX sPLA2. COS-7 cells transfected with either R38- or C38-containing expression vectors were grown at 30&#176;C or 37&#176;C for 72&#160;h. The total amount of hGX sPLA2 protein was then quantified in the cell lysate (<bold>a</bold>) and supernatant (<bold>b</bold>) using the TR-FIA assay as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. <bold>c</bold> COS-7 cells transfected with either the R38- or C38-containing or empty expression vectors were grown at 30&#176;C or 37&#176;C for 72&#160;h, and hGX sPLA2 activity was measured in cell supernatants as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Cells transfected with the empty vector showed no detectable hGX sPLA2 protein or enzyme activity (not shown)</p></caption>
###xml 1780 1780 1720 1720 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="109_2009_483_Fig5_HTML" id="MO5"/>
###xml 1067 1780 1031 1720 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="61">Effect of temperature cell growth on the expression of hGX sPLA2. COS-7 cells transfected with either R38- or C38-containing expression vectors were grown at 30&#176;C or 37&#176;C for 72&#160;h. The total amount of hGX sPLA2 protein was then quantified in the cell lysate (<bold>a</bold>) and supernatant (<bold>b</bold>) using the TR-FIA assay as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. <bold>c</bold> COS-7 cells transfected with either the R38- or C38-containing or empty expression vectors were grown at 30&#176;C or 37&#176;C for 72&#160;h, and hGX sPLA2 activity was measured in cell supernatants as described in <xref rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>. Cells transfected with the empty vector showed no detectable hGX sPLA2 protein or enzyme activity (not shown)</p></caption><graphic position="anchor" xlink:href="109_2009_483_Fig5_HTML" id="MO5"/></fig>
Reduction of cell growth temperature to 30degreesC has been shown to rescue protein expression and folding of different proteins [26]. To validate our hypothesis that the mutation affects the folding of the hGX sPLA2, we performed parallel transfections of COS-7 cells with the C38 and R38 expression constructs and then incubated the cells at either 30degreesC or 37degreesC. Results of TRF-IA assays showed that incubation of cells at 30degreesC dramatically increased the amount of the C38 protein in both cell lysate and supernatant when compared to cells incubated at 37degreesC (Fig. 5a, b). As expected, no major effect was observed for the R38 construct (Fig. 5a, b). However, the increased amount of C38 protein was not accompanied by an increased level of sPLA2 activity in the cell supernatant (Fig. 5c), indicating that the overexpressed protein produced at 30degreesC is not catalytically active. Together, these results suggest that the C38 mutation results in the production of a defective enzyme, which is likely to be misfolded and rapidly degraded. Fig. 5Effect of temperature cell growth on the expression of hGX sPLA2. COS-7 cells transfected with either R38- or C38-containing expression vectors were grown at 30degreesC or 37degreesC for 72 h. The total amount of hGX sPLA2 protein was then quantified in the cell lysate (a) and supernatant (b) using the TR-FIA assay as described in "Materials and methods". c COS-7 cells transfected with either the R38- or C38-containing or empty expression vectors were grown at 30degreesC or 37degreesC for 72 h, and hGX sPLA2 activity was measured in cell supernatants as described in "Materials and methods". Cells transfected with the empty vector showed no detectable hGX sPLA2 protein or enzyme activity (not shown)
###end p 60
###begin p 61
###xml 271 272 259 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 291 292 279 280 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 333 356 321 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
###xml 358 359 346 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 573 596 549 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Sec2" ref-type="sec">&#8220;Materials and methods&#8221;</xref>
Effect of temperature cell growth on the expression of hGX sPLA2. COS-7 cells transfected with either R38- or C38-containing expression vectors were grown at 30degreesC or 37degreesC for 72 h. The total amount of hGX sPLA2 protein was then quantified in the cell lysate (a) and supernatant (b) using the TR-FIA assay as described in "Materials and methods". c COS-7 cells transfected with either the R38- or C38-containing or empty expression vectors were grown at 30degreesC or 37degreesC for 72 h, and hGX sPLA2 activity was measured in cell supernatants as described in "Materials and methods". Cells transfected with the empty vector showed no detectable hGX sPLA2 protein or enzyme activity (not shown)
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 341 348 341 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G2A</italic>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G5</italic>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1580 1582 1580 1582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 1905 1906 1905 1906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1908 1910 1908 1910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 2657 2659 2651 2653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 1398 1413 <span type="species:ncbi:10090">transgenic mice</span>
Growing evidence suggests that sPLA2s IIA, III, V, and X are involved in various inflammatory diseases including CAD and cancer [6, 27]. Circulating levels of sPLA2 activity is an independent predictor of death and new or recurrent MI in patients with acute coronary syndrome [28]. Serum levels of sPLA2 GIIA are linked to variations in the PLA2G2A gene while tagging single nucleotide haplotypes reveal a strong association of the PLA2G5 gene with lipid levels (LDL and oxidized LDL) [29, 30]. Considering the simultaneous expression of IIA, III, V, and X enzymes in the atherosclerotic plaque, it becomes challenging to elucidate the pathophysiological roles of each enzyme in the arterial wall. Using a genetic approach, we identified polymorphisms in the gene coding for hGX sPLA2 and examined whether these polymorphisms play an etiological role in CAD. Our study identified eight polymorphisms, one of which results in the substitution of arginine 38 to cysteine (R38C) in the propeptide sequence of the sPLA2. The full open-reading frame of the hGX cDNA encodes for a signal peptide of 21 amino acids followed by a propeptide sequence of 11 amino acids ending with an arginine doublet and a mature acidic protein of 123 amino acids [14]. The R38C polymorphism is located in the propeptide region of the protein near the putative arginine doublet cleavage site. Overexpression of GX sPLA2 in transgenic mice showed that the zymogen form of the enzyme predominates in most tissues, and that certain inflammation-associated proteases may play a role in activating the enzyme [10]. Conversely, recombinant expression of hGX sPLA2 in various eukaryotic cells leads to the predominant release of the active enzyme, making unclear whether the enzyme is secreted in an active form after propeptide removal before secretion or whether the enzyme is secreted as a proenzyme and then matured extracellularly [8, 31]. The fact that R38C mutation may alter the formation of disulfide bonds and thus the folding of hGX sPLA2, led us to examine its impact on sPLA2 protein expression. Fluorescence immunocytochemistry experiments in COS-7 cells transiently transfected with wild-type and mutant hGX sPLA2 cDNAs showed that both proteins are present in ER and Golgi compartments. Analysis of protein expression and enzymatic activity to reveal an active secretion clearly showed that the mutation lowered the total amount of protein produced by COS-7 cells, prevented its efficient secretion, and resulted in low or no detectable enzymatic activity. When transfected cells were grown at 30degreesC, a temperature that rescue the folding of various mutated proteins [26], we observed an increased production of the C38 protein in cell lysate and supernatant of transfected cells, but no increase in sPLA2 enzymatic activity. Together, these results support our hypothesis that the R38C mutation produces a misfolded protein that is catalytically inactive and rapidly degraded.
###end p 63
###begin p 64
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 621 625 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 746 753 746 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
###xml 877 881 877 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gene</italic>
###xml 1299 1306 1299 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLA2G10</italic>
Despite the functional effects observed for the R38C polymorphism at the protein level, no association was observed between this polymorphism and CAD risk or cardiovascular risk factors in the AtheroGene study and the SIPLAC study. This lack of association might be explained by the low frequency of the C38 allele (approximately 3%) and, consequently, the low power of the present studies to detect an association. Furthermore, due to the unavailability of suitable substrates to distinguish between different sPLA2s, the circulating level of GX sPLA2 could not be investigated as an intermediate phenotype in the AtheroGene study. In addition to the R38C polymorphism, we identified other polymorphisms in the putative regulatory region of the PLA2G10 gene. The T-512C was associated with the risk of future cardiovascular event during the prospective follow-up of the AtheroGene cohort. However, this polymorphism was not associated with CAD or MI risk in a case/control setting and did not correlate with any cardiovascular risk factor. This result has thus to be taken with caution and requires further replication in other cohorts. As this polymorphism is located in the putative promoter region of the gene, it might influence the expression level of the enzyme; however, the promoter of the PLA2G10 is still unknown, and thus will be interesting to explore.
###end p 64
###begin p 65
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
Recent studies implicate GX sPLA2 in myocardial ischemia reperfusion injury [11], in allergen-induced airway inflammation [9], and in lung diseases [8]. A possible role of hGX sPLA2 was also suggested in lung and colon carcinogenesis [12, 13]. In this context, functional genetic mutations leading to an alteration of protein expression and/or enzymatic activity may have a profound impact on the pathophysiological role of the enzyme, in particular, by modulating the concentration of lipid mediators produced locally and thus modifying the inflammatory process in diseases like atherosclerosis and cancer.
###end p 65
###begin title 66
Acknowledgements
###end title 66
###begin p 67
This study was supported by the Institut National de la Sante Et de la Recherche Medicale and by the fellowships from the Fondation pour la Recherche Medicale (SPF20080512033) to SAK and (FDT2000910244) to SG. The study was also supported by an ANR program (ANR 2006 Physiopathologie des maladies humaines: sPLA2/ATHEROSCLEROSE) to GL and EN, and in part by the CNRS and the Association pour la Recherche sur le Cancer to GL. EN and GL are directors of research of the Centre National de la Recherche Scientifique. We also thank the "Plate-forme d'Imagerie Cellulaire Pitie Salpetriere" for confocal imaging, and the "Plate-forme Postgenomique P3S".
###end p 67
###begin p 68
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 68
###begin title 69
References
###end title 69
###begin article-title 70
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease
###end article-title 70
###begin article-title 71
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function
###end article-title 71
###begin article-title 72
Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis
###end article-title 72
###begin article-title 73
###xml 48 63 <span type="species:ncbi:10090">transgenic mice</span>
Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis
###end article-title 73
###begin article-title 74
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation
###end article-title 74
###begin article-title 75
Biochemistry and physiology of mammalian secreted phospholipases A2
###end article-title 75
###begin article-title 76
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice
###end article-title 76
###begin article-title 77
Macrophage secretory phospholipase A2 group X enhances anti-inflammatory responses, promotes lipid accumulation, and contributes to aberrant lung pathology
###end article-title 77
###begin article-title 78
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
Importance of group X-secreted phospholipase A2 in allergen-induced airway inflammation and remodeling in a mouse asthma model
###end article-title 78
###begin article-title 79
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Transgenic expression of group V, but not group X, secreted phospholipase A2 in mice leads to neonatal lethality because of lung dysfunction
###end article-title 79
###begin article-title 80
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice
###end article-title 80
###begin article-title 81
###xml 61 67 <span type="species:ncbi:9606">humans</span>
###xml 139 144 <span type="species:ncbi:9606">human</span>
Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells
###end article-title 81
###begin article-title 82
Potential role of group X secretory phospholipase A(2) in cyclooxygenase-2-dependent PGE(2) formation during colon tumorigenesis
###end article-title 82
###begin article-title 83
###xml 56 61 <span type="species:ncbi:9606">human</span>
Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2
###end article-title 83
###begin article-title 84
###xml 29 34 <span type="species:ncbi:9606">human</span>
On the binding preference of human groups IIA and X phospholipases A2 for membranes with anionic phospholipids
###end article-title 84
###begin article-title 85
###xml 86 91 <span type="species:ncbi:9606">human</span>
The proinflammatory mediator platelet activating factor is an effective substrate for human group X secreted phospholipase A2
###end article-title 85
###begin article-title 86
Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation
###end article-title 86
###begin article-title 87
Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A(2)
###end article-title 87
###begin article-title 88
A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM study
###end article-title 88
###begin article-title 89
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease
###end article-title 89
###begin article-title 90
Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease
###end article-title 90
###begin article-title 91
Specific haplotypes of the P-selectin gene are associated with myocardial infarction
###end article-title 91
###begin article-title 92
###xml 86 91 <span type="species:ncbi:9606">human</span>
Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum
###end article-title 92
###begin article-title 93
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor
###end article-title 93
###begin article-title 94
Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity
###end article-title 94
###begin article-title 95
Pharmacological chaperones: potential treatment for conformational diseases
###end article-title 95
###begin article-title 96
###xml 77 82 <span type="species:ncbi:9606">human</span>
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate
###end article-title 96
###begin article-title 97
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes
###end article-title 97
###begin article-title 98
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study
###end article-title 98
###begin article-title 99
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study
###end article-title 99
###begin article-title 100
Neuronal expression and neuritogenic action of group X secreted phospholipase A2
###end article-title 100
###begin p 101
Claire Perret and Ikram Jemel contributed equally to this paper.
###end p 101

